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INTRODUCTION 
Ever since 1967, when McDevitt and Sela reported that the immune 
response to a synthetic peptide, (T,G)-A—L, was controlled by a gene they 
designated as immune response gene-1 (Ir-1), numerous investigators have 
sought to locate and identify other Ir genes. They have attempted to 
characterize the effect(s) these genes exert on the imnunogenicity of a 
protein, or antigen, and some have tried, with varying degrees of success, 
to elucidate the areas, or epitopes, on the antigen that are recognized by 
an animal's immune system. The major thrust of this research was to 
identify genes and epitopes involved in the murine response to human 
hemoglobins (Hbs). 
The H-2 Complex 
In 1936, Peter Gorer described a set of molecules on the surface of 
mouse red blood cells (RBCs). He defined these molecules by his ability to 
raise antisera against them (Gorer, 1936)and the ability, or inability, to 
transfer cells from mice carrying one type of molecule into mice having 
either different or similar RBC molecules (Gorer, 1937). The molecules 
were later named histocompatlbility-Z (H-2) antigens and the region of the 
genome where they resided, which was located on chromosome 17, named the 
major histocompatibility complex (MHC) (Gorer et al., 1948). Further work 
demonstrated the existence of similar regions in other species, HI,A in the 
human, RT-1 in the rat, 2 ii: the chicken, SLA in the pig, etc., as well as 
the presence of many "minor" histocompatibility systems which played lesser 
roles in the immune response (Klein, 1975). 
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The H-2 complex Is located In the middle portion of chromosome 17 
(Figure 1). Also on chromosome 17 are four other groups of loci: (1) 
those Involved In controlling embryonic differentiation (T, t, Kb, Fu and 
qk); (2) loci controlling hair growth (th and thf); (3) loci determining 
the Isozymes of various enzymes (Pgk-2, Ce-2, Ap-1, Glo-1, Neu-1, Map-2 and 
Upg-1); and, (4) thy-2, a locus that encodes a thymus cell antigen (Klein, 
1979 and Klein et al., 1982). 
Up until a few years ago, the H-2 complex was thought to be divided 
Into 4 major areas, K, I, S, D (see Figure 2a) (Klein, 1975). Each of 
these four areas, and subsequent subreglons within them, were defined using 
recombinant congenlc mice which had undergone recombination events within 
their MHC. As the work progressed, however, so many subreglons and new 
regions were being proposed that a map of the H-2 complex became, as Jan 
Klein suggested, a "Madman's alphabet" (Klein e£ , 1983a). In an 
attempt to clear up the ensuing confusion, Klein et al., (1981) presented a 
map based on the gene products produced by the different areas. The H-2 
loci were grouped into three classes, I, II and III, and the Tla region, 
found to the right of the D region, was included as part of the MHC (see 
Figure 2b) (Stelnmetz and Hood, 1983 and Hood et al., 1983). 
Class I antigens were defined as those molecules encoded by the K, D, 
L, Qa-2, Qa-3 and Tla subreglons. These proteins had molecular weights of 
approximately 45,000 daltons and were glycoproteins noncovalently associ­
ated with a 12,000 dalton molecular weight (MW) protein, Gg-microglobulln, 
which was coded for by a non-MHC gene, H-3, located on chromosome 2 (Klein, 
1975 and Mlchaelson, 1983). 
The class I proteins can further be divided into two subgroups, those 
Fu tf Glo—X 
Tla 
H-2K H-2D i Ce-2 thf 
13.5 
Figure 1. Abbreviated genetic map of chromosome 17 (Klein, 1975; Klein and Nagy, 1982) (The 
loci from left to right are centromere (#), brachyury (T^), quaking (qk), fused (Fu), 
tufted (tf), knobby (Kb), glyoxylase-1 (Glo-1), histocompatibility-2K (H-2K), 
histocompatibility-2D (H-2D), thymus-leukemia antigen (Tla), phosphoglycerate kinase-2 
(Pgk-2), kidney catalase (Ce-2), acid phosphatase-liver (Apl), -mannoside processing-2 
(Map-2), thin fur (thf). Brackets indicate the order of loci is not known) 
K I s D 
Figure 2a. Enlarged H-2 complex (Schreffler, 1979; Klein et al.. 1981) 
LOCI K Ag Eg E^ (C4,S1p) (D.L.R) Q.a-2,3 
C L A S S  I  I I  I I  I I  I I  I I I  I  I  
COMPLEX 
REGION K I S D da 
Figure 2b. Genetic maps of the MHC in mouse (For symbols, see text) 
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encoded In the K, D and L regions and those encoded in the Qa-2, Oa-3 and 
Tla regions. The first group, the classical transplantation antigens, are 
highly polymorphic (Steinmetz and Hood, 1983) and are present on virtually 
all somatic cells of the mouse. The Qa and Tla antigens, on the other 
hand, are much less polymorphic and are expressed preferentially on B cells 
and T cells, for the Qa antigens, and on macrophages, for the Tla antigens 
(Flaherty, 1981). Whereas many functional roles of the classical class I 
antigens, K, D and L, are known (see Table 1) (Klein et al., 1981), the 
functions of the Qa-3 and Tla antigens have not been established. A 
possible role of the Qa-2 antigens may be an involvement in early embryonic 
development (C. Warner, Iowa State University, unpublished, 1983). 
The biochemical organization of class I antigens has been reviewed by 
Hood £t £l., 1983 and more recently, by Steinmetz and Hood (1983). The 
molecule has been found to be composed of five domains or regions: three 
external, one transmembrane and one Internal (see Figure 4). The three 
external domains are approximately 90 amino acids each, the transmembrane 
domain and cytoplasmic domains 40 and 30 amino acids respectively (Uehara 
et al., 1980; Malissen e^ al., 1982; and. Hood e^ , 1982). The two 
N-termlnal domains (o^, a^) are highly variable when compared to the 
corresponding domains of other class I molecules. The third external 
2 domain (o^) is the noncovalent attachment site for 3 -microglobulin and is 
much less polymorphic (Orr al., 1979). Preliminary x-ray crystallo-
graphlc evidence suggest the pairing of the and domain and the 
domain and gg-mlcroglobulin in a two-fold axis of symmetry, similar to 
antibody domains (Hood ^  £l., 1983). 
One function of the H-2 class I antigens is to provide a context for 
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Table 1. Involvement of H-2 molecules In various functions 
TRAIT MOLECULE 
K A 
(AaAg) 
E 
(EoiEB) 
J S D 
Serologically detectable antigens + + + -/+ + + 
Rejection of allografts + +/- +/- ? - + 
Cell-mediated lympholysis + +/- +/- ? - + 
Mixed lymphocyte reaction -/+ + + /- -/+ 
-
-/+ 
Control of immune response -/+ + + -/+ - -/+ 
Control of T-B collaboration - + + ? - -
Restriction of T^-cell specificity + - - - - + 
Restriction of T^-cell specificity - + + ? - -
Control of complement activity - - - - + -
+ = indicate strong involvement of molecules in expression of the trait. 
-/+ and +/- = indicate weak and intermediate involvement, respectively. 
- = indicate no involvement. 
! 
8 
*3 
Figure 3. Diagram showing the domain organization of class I MHC mole­
cules (g.m, 02 microglobulin; other combinations of Greek 
letters and numbers Indicate individual MHC domains; M, 
membrane, C, cytoplasm) 
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antigens to be recognized by the receptors of cytotoxic T cells (T^)(Klein 
and Nagy, 1982). During viral infections, for example, the cell must 
Interact with the foreign antigen as well as with the cell's class I 
antigens. If the transplantation antigen is of a different haplotype than 
that found on the cell, no killing occurs. This phenomenon has been 
called H-2 restriction (Zinkernagel and Doherty, 1979) . 
Ivanyl and Demant (1981) have demonstrated the presence of at least 2 
K and 3 D loci in mice bearing the H-2^ haplotype. This is in contrast to 
what has been shown in the Qa and Tla region where more than 30 loci have 
been described (Winoto eit aj^., 1983). These numbers may also vary from 
strain to strain since recent evidence has suggested that C57B1/10 mice 
(H-2^) have only half the number of class T genes as do mice with the H-2^ 
haplotype (Hood ^  al., 1983). It has also been demonstrated that a given 
allele of the K gene is no more similar to another K allele than it is to a 
given nonallele H-2D gene (Weiss jet , 1983). A possible mechanism for 
the extreme polymorphism is the occurrence of gene conversion events (i.e. 
the transfer of nucleotides between genes) between the K or D allele and 
other class I genes found In the Qa-Tla region. Such an event has been 
shown to have happened in the mutation of the H-2K^ gene to H-2K^"'^. The 
comparison of nucleotide sequences found seven nucleotide changes resulting 
in three amino acid differences. These seven changes all occurred within a 
13 nucleotide region of the genome. When this mutant region was compared 
to a nonmutant region in the H-2T..^ gene, a striking homology was observed 
(Weiss e^ £l., 1983), thus suggesting gene conversion. 
The second class of molecules, class II, have previously been defined 
as la or I-assoclated antigens. Thus far, four la genes have been found in 
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the I region of the MHC (see Figure 2b), three that map to the I-A subre-
gion, Aa, Ag, Eg, and one in the I-E subregion, Ea. Â0 and Ea produce 
glycoproteins with a 34,000 dalton MW, while Aa and Eg code for 28,000 
dalton MW glycoproteins. The noncovalent association of Aa with Ag and Ea 
with Eg form the I-A and I-E molecules (see Figure 4) (Klein et. al., 1983b) 
which have been demonstrated to be involved in various immune functions 
(Table 1). Within the cytoplasm, both these molecules have been shown to 
associate with a highly conserved 31,000 dalton protein termed the invari­
ant chain, li (Jones et al., 1979 and Koch et al., 1982). The orientation 
of these genes within the I region has recently become a source of 
controversy. Rose and Cullen (1981) suggested that the order was Aq, Ag, Eg 
and Ea. It now appears, on the basis of gene cloning and sequencing, that 
the correct order is A3, Aa, Eg and Ea (Hood et al., 1983). 
Originally, the T region had been subdivided into five distinct sub-
regions, A, B, J, E, C, by recombinational events. It has now been estab­
lished that the I-B region (Baxevanis ^  al., 1981 and Steinmetz et al., 
1982) does not exist and that the existence of the I-C region is at best 
speculative (Klein et al., 1983a, b). 
The J region has also been a source of controversy. Whereas, the 
existence of the B and C loci were based on the response to particular 
antigens (Lieberman and Humphrey, 1972 and Merryman and Mauer, 1975), the 
I-J region was shown, serologically, to exist. Its gene product(s) were 
said to be expressed both on suppressor T cells (T ) and a T factor (TsF) 
(Tada e£ al., 1976) and monoclonal antibodies had been developed against 
I-J polypeptides (Waltenbaugh, 1981). Yet, when Steinmetz and his col­
leagues (1982) analyzed, by restriction mapping, nine strains of congenlc 
11 
0,2 (32 
Figure 4. Diagram showing the domain organization of Class II MHC 
molecules (Combinations of Greek letters and numbers indicate 
individual MHC domains; M, membrane, C, cytoplasm) 
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mice, previously used to define the left and right boundaries of the I 
region, they found the I-A and I-E regions separated by only 3.4 kilobases 
(kb) of DNA. They further pointed out that the left, or proximal, end of 
the Eg gene resides in at least 2.4 kb of this region, leaving only 1 kb, 
or 1000 bases, to code for the I-J subregion, seemingly an inadequate 
amount (Kronenberg et al., 1983). Moreover, the I region has recently been 
completely sequenced and no evidence for an I-J gene was found (L. Hood, 
California Institute of Technology, unpublished, 1983). Two possible 
explanations given for this paradox are that the I-J gene is actually 
located elsewhere, or that it is a known product of the I region which has 
pleiotropic functions. The first possibility would require multiple gene 
recombinations and no satisfactory evidence has yet been given in its 
defense. Recently, however, Ikezawa and coworkers (1983) have provided 
evidence for the second possibility. 
Baxevanls et £l., (1981) previously found that mouse strains expressing 
b k 
the alleles Eg and Eg generated suppressor T cells when exposed to 
lactate dehydrogenase-B (LDH-B), which inhibited the Iji vitro proliferative 
response of LDH-B specific T^ cells. In order to be activated, the Tg 
cells needed to recognize the antigen in conjunction with the Eg encoded 
protein. They could then secrete suppressor factors (TsF) which suppressed 
the Tjj cell. Further work demonstrated (Ikezawa et al., 1983) that, in 
fact, two suppressor factors were elaborated by the Tg cell. These factors 
consisted of two polypeptide chains, an antigen binding chain (ABC) specif­
ic for LDH-B, and an I-region MHC chain, either Ag (TsF-A) or Eg (TsF-E). 
T^ cells that needed to recognize the I-A molecule would recognize the 
TsF-A, whereas those restricted to the I-E molecule would recognize TsF-E. 
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They also demonstrated that the ABC was not or and suggested that it 
might be the elusive T cell receptor. Another group (Koch et al., 1983) 
has also demonstrated that the G chains, of "la" antigens found on T cells, 
are not associated with the a chains but to another protein with an approxi­
mate MW of 31,000 daltons. 
Serologically, the Ag and Eg components of the factors were found to 
react with antisera that recognize B cell derived Ag and Eg chains. Unlike 
their B cell counterparts, however, they also cross reacted with antl-J 
antisera, thereby suggesting that the I-J determinants were encoded in the 
Eg and Ag loci and that the Ag and Eg chains were modified, within the Tg 
cell, to express them. 
Ir Genes 
It is widely accepted that I-region genes play a role in determining 
whether an animal will, or will not, respond to an antigen. The response 
to synthetic polymers such as (TG)-A—L (McDevitt and Sela, 1967), GAT 
(Kapp et al., 1973), GLA (Klpps et al., 1980) and, GL0 (Dorf et al., 1975), 
have all been shown to be under the control of I-region genes. Responses 
to naturally occurring proteins such as myoglobin (Berzofsky, 1978, Okuda 
^ al., 1979), lysozyme (Hill and Sercarz, 1975), Insulin (Bucy and Kapp, 
1981), collagen (Hedrick and Watson, 1980) and the H-Y histocompatibility 
antigen (Simpson and Gordon, 1977), have also been shown to be under the 
control of I region genes. A major question that has yet to be answered is 
by what mechanism these Ir genes regulate the Immune response, or, in other 
words, what causes a nonresponder animal not to make antibody to an anti­
gen, or its T cells not to proliferate when incubated with the antigen? 
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Two main hypotheses have been presented as models for the mechanism of 
Ir gene control and T cell antigen recognition: determinant selection and 
clonal deletion (Dos Rels e^ al., 1983). Determinant selection stated that 
the Ir gene products are functionally expressed at the level of the antigen 
presenting cell (APC) and that the ability to select and display a specific 
antigen epitope to the Immune T cell was an Ir gene function. The clonal 
deletion model said that Ir gene control was a result of the restriction of 
the T cell repertoire which occurred during the Induction of self-tolerance 
(Dos Rels et al., 1983). In other words, T cells that were capable of 
recognizing self-la antigens, or self-Ia-self-antlgen complexes, were 
eliminated during development as the animal tolerlzed Itself to self 
antigens. 
The first hypothesis, determinant selection, was proposed by Barcinski 
and Rosenthal (1977). They demonstrated, using synthetic and native 
peptides of insulin, that strain 2 guinea pig T cells recognize different 
sites on the insulin molecule than do the T cells of strain 13 guinea pigs. 
They were unable, however, to distinguish the antibodies produced from 
strain 2 animals from those of strain 13. They interpreted these results 
as indicating that Ir genes function by selecting the regions of a molecule 
to be recognized by T cells and that this recognition exists at the level 
of the macrophage (Rosenthal ^  al., 1977). 
Ifhereas, no one has yet disproven the determinant selection hypothe­
sis, much work has been done to present a strong case in favor of the 
clonal deletion model. Ishil et al., (1983), have demonstrated that nonre-
sponslveness to certain antigens can be overcome by the use of allogeneic 
APCs. They suggested that association of antigen with self-la molecules 
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would lead to an Inability to respond, since the T cell repertoire would 
have been depleted of T cells capable of recognizing syngeneic la 
molecules. Clark and Shevach (1982) have shown a similar phenomenon using 
insulin, the same antigen previously used by Rosenthal eit , (1977) to 
demonstrate determinant selection. In a recent series of papers, Aharm 
Friedman and his associates described the molecular events involved in the 
processing of avidln by APCs. After concluding that the T cell prolifera­
tive response was under the control of genes found in the I-A region 
(Friedman and Cohen, 1983) , they demonstrated that the processed avidln 
(PA) from nonresponder APCs was no different from that found produced by 
responder APCs, and that the Inability of nonresponder mice to respond to 
the avidln was due to a loss of avidin-speclflc T cells from the lymphocyte 
repertoire, again suggesting the deletion of specific clones of lymphocytes 
(Friedman e^ al., 1983a). In a further study (Friedman et a]L,, 1983b), it 
was found that the processed antigen was reverslbly associated with an 
la-llke molecule. Since no difference in the processing of the antigen was 
found, the la-llke molecule, alone or in complex with the antigen, was 
proposed as the moiety responsible for recognition, or nonrecognltlon, by 
proliferating T cells, again suggesting that Ir gene effects occurred at 
the level of the T cell, i.e. clonal deletion, and not at the level of the 
macrophage or APC. 
Whether such an antigen-la complex is also recognized by the B cell 
has been a matter of controversy (Singer and Hodes, 1983). Katz et al., 
(1975) have demonstrated that the differentiation of B cells into antibody-
producing plasma cells not only required MHC compatibility, but, more 
specifically, required I region identity with their cells. Mltchlson 
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(1971) and others (Rajewsky et al., 1969) showed that such an activation 
required the recognition of different determinants by the T cell and B 
cell, thereby forming an antigenic bridge between them and establishing 
effective T -B cell collaboration. In other studies, Katz (1977) and 
Sprent (1976), put forth the hypothesis that the activation signal was 
elicited by the cells by their simultaneous recognition of carrier 
determinants on the antigen and syngeneic MHC determinants expressed by B 
cells. Other groups (Erb and Feldmann, 1975; and McDougal and Cort, 1978), 
however, demonstrated that while cells were MHC-restrlcted in their 
interaction with the APC, they lost that restriction with B cells. This 
controversy was partially explained when Melchers et al., (1980), demon­
strated that the activation of small resting B lymphocytes was MHC-
restrlcted, whereas the differentiation of these activated B cells into 
plasma cells was not. Further clarification was presented by Singer et 
al., (1982). They proposed that different subsets of B lymphocytes existed 
that differed in their requirement for MHC-restrlcted interactions with T^ 
cells. If the subset had Lyb5, a B cell differentiation antigen, on its 
surface, T^ cell recognition of B cell MHC molecules was not required. 
Lyb5 B cells, however, did require such a recognition. It had further 
been observed (Asano e£ ^ ., 1982) that a monoclonal T cell line could, 
•F* MM 
under different conditions, interact with either Lyb5 or Lyb5 B cells, 
but in a MHC-unrestricted or MHC-restrlcted way, respectively. 
Lymphokines have also been shown to play a role in the B cell-plasma 
cell transition. A recent paper (Noelle £t al., 1983) suggested that after 
a B cell is activated to a B cell blast, differentiation occurs in the 
presence of lymphokines. They further emphasized that it was the nature of 
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the initial activation signal that determined whether a B cell can undergo 
terminal differentiation. If the initial signal were not "linked recogni­
tion," the antigen bridge concept presented above, then the B cell could 
only proliferate and not differentiate. Only when linked recognition 
occurred was there differentiation. 
All of the interactions mentioned above have been shown to play a role 
in the forming of a humoral and cellular immune response. Another factor 
necessary for the successful initiation and maintenance of the response is 
the complexity and antigenicity of the antigen itself. Random poly­
peptides, such as GL0 and GLA, have been used as immunogens, yet their 
random nature has limited the extent to which they can be used as probes in 
the determination of the antigenic sites recognized by the T and B cell. 
There have been some successes, however. Klpps e^ al., (1980) have demon­
strated that the vast majority of antl-GLA antibodies are directed against 
the GL portion of the molecule, whereas the determinants recognized by T 
cells in a proliferation assay are found within both the GA and GLA moi­
eties. This result was similar to other GL-contalning antigens such as GL0 
(Klpps et. » 1977) . 
Native Protein Antigens 
The use of native proteins, whose structures were well-characterized 
and amino acid sequences known, eliminated the variability of the synthetic 
random polypeptides. Two such proteins, lysozyme and myoglobin, have been 
extensively studied and insights into their antigenic structures developed. 
Sperm whale myoglobin (sMb), a protein containing 153 amino acid 
residues linked in a tightly helical, single polypeptide chain (Kendrew 
al.» 1961), had its complete amino acid sequence established in 1965 
(Edmundson, 1965). Hen egg-white lysozyme was found to contain 129 amino 
acids and be crosslinked by four disulfide bonds (Canfleld and Liu, 1965), 
something not found in Mb. 
Two major groups explored the antigenic properties of sMb, Zouhair 
Atassi's at the Mayo Clinic in Rochester, MN and Jay Berzofsky's at the 
National Institutes of Health in Bethesda, MD. Each group approached the 
definition of antigenic determinants in different ways. Atassi's group 
used affinity chromatography, binding a series of chemical modifications of 
the protein, or synthetic polypeptides corresponding to overlapping 
sequences of the Mb primary structure, to sepharose, and then selectively 
absorbing out radlolabelled polyclonal antibodies (Twining and Atassl, 
1979). Berzofsky's group utilized the numerous Mb variants found 
throughout mammalian species and suggested that changes in the primary 
sequence would either abrogate, or greatly reduce, the ability of anti-sMb 
antibodies to bind to the variant Mbs. The changes would also decrease the 
T cell proliferative response seen when sMb-prlmed T cells were incubated 
with the other Mbs (Berzofsky et al., 1982). 
The results of Atassi's group suggest the presence of 5 antigenic 
sites on the Mb molecule. These five sites occupy the following regions: 
site 1, residues 15-22; site 2, residues 56-62; site 3, residues 94-99; 
site 4, residues 113-119; and site 5, residues 145-151. Using polyclonal 
antisera raised in rabbits and goats (Atassl, 1975) and later in mice 
(Twining et , 1981) , they found that 99% of the antibodies could be 
absorbed to affinity columns coated with the five peptides, suggesting that 
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only linear sequential determinants were found in the sMb molecule, and 
that the antigenicity of the determinants is independent of the immunized 
species and is Inherent in the three-dimensional locations of the antigenic 
determinants (Twining et al., 1981). They have also been able to raise 
monoclonal antibodies to these specific peptides, that then recognize the 
native molecule, by using the peptide as an immunogen (Young et al., 
1983a). They have further demonstrated that the immune response to the 
individual antigenic sites are controlled by separate Ir genes (Infante et 
al., 1981 and Okuda e^ al., 1979). 
Berzofsky et al., (1982) have approached the mapping of the antigenic 
sites by first developing monoclonal antibodies (Mab) to the protein and 
determining their specificity. In doing so, they established that the Mb 
antigenic sites were conformational in nature, since cyanogen bromide 
cleavage fragments of sMb did not react with some Mab. They also proposed 
that some were topographical, or discontinuous, determinants, i.e. the 
sites were composed of amino acid residues lying far away from each other 
in the primary structure, but brought into close proximity by the folding 
of the molecule (Berzofsky et al., 1982 and Lando et al., 1982). The 
residues involved were 4 and 79 for site 1; 83, 144, 145 for site 2; and 
lys 140 for site 3. They also assumed that the site 2 determinant is 
concave, since it lies in a crevice of the molecule and which would lead to 
the assumption that the antibody combining site must be convex. 
Both groups have presented strong evidence for their contradictory 
views. Atassi's group has shown the inherent antigenicity of the five 
proposed sites in various species of animals (Twining e^ al., 1980). They 
have also shown that some peptides, nonantigenic in the Intact molecule by 
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their criteria, can be used as effective immunogens if injected on their 
own (Young e£ al^., 1983b). Monoclonal antibodies developed against such 
peptides were found to react with the native sMb molecule. Since 2% of the 
polyclonal antibodies were not absorbed by the affinity columns, those 
areas recognized by Berzofsky's group may have corresponded to these 
"nonantigenic" sites. Additionally, the assumption made on the part of 
Berzofsky's group, that nondeterminant residues would not affect the 
binding of antibodies, may have been an oversimplification. It has also 
been reported (Lando and Reichlin, 1982) that neoantigenic determinants 
appear on Mb after macrophage or APC processing, further complicating the 
picture and suggesting that the native conformation may have less to do 
with antigenicity than previously thought. 
Lee and Atassi (1977), have demonstrated the presence of confor­
mational and topographical determinants on lysozyme as well. They used a 
similar approach as that used In Mb, but synthesized peptides that simulat­
ed conformational, rather than sequential, determinants and showed that at 
least one site was made up of seven widely spaced amino acids, 20, 21, 116, 
113, 114, 34 and 33, in that order. They had shown previously that these 
amino acids were brought close together by a disulphide bridge between 
cysteine 30 and cysteine 115. Hill and Sercarz (1975) suggested an addi­
tional determinant located in the area 99-103, with some interaction of 
residues 19 to 21. 
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Hemoglobin 
One molecule that has recently been used as an Immunogen is human 
adult hemoglobin (Hb). It is different from the preceding molecules 
discussed since it has a quarternary structure, while they were all mono-
meric. Hb has been extensively studied and its three-dimensional structure 
is known. It has been shown to have a MW of 67,500 daltons and to be 
comprised of 2 a chains having 141 amino acids each and 2 g chains, each with 
146 amino acids. Each chain surrounds a heme group and is arranged in a 
two-fold axis of symmetry (Figure 5) (Perutz, 1970). The amino acid 
sequences for Hbs from numerous animals have been determined and found to 
be highly conserved, with a few amino acids found throughout mammalian Hbs 
(Table 2a, 2b). The ot and 3 subunit's tertiary structures are similar to 
that of myoglobin, with each subunit containing seven or eight helical 
regions, respectively, separated by nonhelical regions and additional 
nonhelical regions found at the carboxy and amino termini (Baldwin, 1980). 
The molecule is approximately spherical in shape with dimensions of 65 x 55 
X 50 A, with the subunits held together by nonpolar interactions, some 
electrostatic or salt bridges, and hydrogen bonds (Weissbluth, 1974). 
There are contacts between both like and unlike chains, though the like 
chain interactions are rather tenuous. The contacts between unlike chains 
are much more extensive and are mostly hydrophobic. Two types of contacts 
exist: (or g^) and (or g^). When the Hb tetramer 
dissociates, it tends to do so along the contacts, leaving g^ 
dimers (Lehmann and Huntsman, 1974). 
Two basic conformations of the Hb molecule have been shown to exist. 
Figure 5. The three-dimensional structure of human adult Hb (Darkened circles indicate amino acid 
residues involved in some variant HbS.) 
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Table 2a. Abbreviations used to denote different amino acids 
A - alanine (ala) 
B - aspartic acid (asp) or asparagine (asn) 
C - cysteine (cys) 
D - aspartic acid 
E - glutamic acid (glu) 
F - phenylalanine (phe) 
G - glycine (gly) 
H - histidine (his) 
I - isoleucine (ileu) 
K - lysine (lys) 
L - leucine (leu) 
M - methionine (met) 
N - asn 
P - proline (pro) 
0 - glutamine (gin) 
R - arginine (arg) 
S - serine (ser) 
T - threonine (thr) 
V - valine (val) 
W - tryptophan (trp) 
Y - tyrosine (tyr) 
Z - gin or glu 
Table 2b. Amino acid sequences for the a—chains of five mammalian Fbs (for symbols, 
see Table 2a) 
Human 
Rabbit 
Goat 
Horse 
Mouse 
Human 
Rabbit 
Goat 
Horse 
Mouse 
Human 
Rabbit 
Goat 
Horse 
Mouse 
Human 
Rabbit 
Goat 
Horse 
Mouse 
1 10 20 30 
V L S P A D K T N V K A A W G K V G A H A G E Y G A E A L E R M F L S F P T T  
I - T E - I - S - G V G 
A — B — S B G B — AG Z 
A S G G 
G E S - I I - G A 
40 50 60 70 
K T Y F P H F D L S H G S A Q V K G H G K K V A D A L T N A V A H V D D M P N  
F T E - I - A S Q K G - L L - G 
B Z Q A K G — L — B L — G 
A G L G — L L — G 
V A G - L L - G 
80 
A L S A L 
T — 
B — 
D — 
S D L H 
90 
A H K L R V D P V N 
100 
F K L L S H C L L V T L  
N 
110 
A A H L P A E 
— N - V - S — 
— C B D 
— V N D 
— S - H D 
N3 
120 130 140 
T P A V H A S L D K F L A S V S T V L T S K Y R  
N 
D B 
S 
Table 2c. Amino acid sequences for the g-chains of five mammalian Hbs (For symbols, see 
Table 2a) 
Human 
Rabbit 
Goat 
Horse 
Mouse 3 
Human 
Rabbit 
Goat 
Horse 
Mouse 
Human 
Rabbit 
Goat 
Horse 
Mouse 
Human 
Rabbit 
Goat 
Horse 
Mouse 
1 10 20 30 40 
V H L T P E E K S A V T A L W G K V N V D E V G G E A L G R L L V V Y P W T Q R  
S S E 
A Z Z - A G F K - B Z A Z 
— Q — S G A L D E E 
H A A S G A G 
41 
F F E S F G D L S 
Z 
D 
Y - D 
H 
50 
T P D 
S A N  
S A B 
ï! - G 
S A S  
A V M G 
— N 
— B 
N P K 
60 
V K A H G K K V L 
B A 
- I 
70 
A F 
S - G 
D G L A H 
E S — 
B - M K — 
E - V H — 
N — 
80 
D N 
B B 
81 90 100 110 120 
L K G T F A T L S E L H C D K L H V D P E N F R L L G N V L V C V L A H H F G K  
K I S 
Z Z B B - Z B - K B B R - G S S 
A Z B B - Z B B A V R 
S M I - I G 
121 130 140 
E F T P P V Q A A Y Q K V V A G V A N A L A H K Y H  
0 
Z 
D 
D 
L L Z - Z F Z 
E L S 
A A F — 
B 
^ Mouse g-chain represents the g chain of B10.D2 mice, B major. 
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the oxygenated form and, conversely, the deoxygenated form. When the Hb 
molecule loses Its 0^, the a and B chains move relative to each other. In 
the case of the contact, this shift was minimal and did not signifi­
cantly effect the overall structure. The movement of the contact, 
however, caused displacements of contact points of up to 7A (Weissbluth, 
1974). 
Whereas the Mb molecule and the Hb components are very similar, their 
ability to bind oxygen is not. Both Mb and Hb can bind, on a per weight 
basis, the same amount of 0^ at high 0^ pressures; however, the Hb will 
lose its Og much more readily at low 0^ tensions. The binding of 0^ to 
each Hb subunit is cooperative; that is, the binding of one Og to a heme 
group will affect the binding of 0^ to the other hemes. This allows for 
the release of approximately 5 times the amount of oxygen that Mb would 
release in tissues with low oxygen tension (Perutz, 1979). 
Three types of Hb are found in normal adults, HbA^, HbA^ and HbF. 
HbAj, described above, consists of 95-99% of the total normal adult Hb 
concentration. HbA^, consisting of 2 a and 2 <S chains, makes up 1-3.5% of 
the Hb, while HbF, 2 a and 2 y chains, or fetal Hb, makes up less than 1%. 
HbF normally makes up 65-95% of the total Hb concentration at birth and 
steadily decreases into adulthood (Lehmann and Kynoch, 1976). The homology 
between the a, g, 6, and y chains is high (Table 3). 
A major advantage in using Hb as an antigen resides in the over 200 Hb 
variants found throughout the world. Many differ in only one or two amino 
acids and therefore offer a chance to dissect the determinants recognized 
by the immune system. One such variant is HbS or sickle-cell Hb. 
HbS was initially identified by Pauling and his associates (1949) as 
Table 3. Comparison of the amino acid sequences of the four different subunits 
of human hemoglobin (For symbol definitions, see Table 2a) 
1 5 10 15 20 25 30 35 
3  V  H L T P E E K S A V T A L W G K V * * N V D E V G G E A I . G R L L V V Y  
a -^L* S-AD-TN-K-A GAHAG-Y-A F. - M G L S F 
6 T N ** A 
Y  G  - F  - E - D - A T I - S  *  *  E D A  T  
36 40 45 50 55 60 65 70 
g  P W T Q R F F E S F G D L S * T P D A V M G N P K V K A H G K K V L G A F S  
a  - T - K T Y F P H - D L S H G * * * * * * * S A N  G  A  D  - L  T  
S * 
Y D * T S L G 
75 80 85 90 95 100 105 110 
B  D G L A H L D N L K G T F A T L S E L H C D K L H V D P E N F R L L G N V L  
a  N  A  V  V - D M P N A L S A  D  A  H  R  V  K  S  H  C  -
5 S N 
Y  - A I - K  N  K  
115 120 125 130 135 140 146 
6  V C V L A H E F G K E F T P P V N A A Y N K V V A G V A N A L A H K Y H  
a  L  V  T  A  - L  P  A  A - H - S L D - F L - S  —  S T V - T S - Y R  
S R N N M : 
Y - T I E S W M - T A S S S R 
^ Solid line indicates homology with the 3 chain at that position. 
* indicates the presence of a "Braunitzer gap" to enhance sequence 
homology. 
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an abnormal hemoglobin from patients with sickle cell anemia and was found 
to differ from normal Hb by a single amino acid difference in the g chain, 
where a valine was inserted as the sixth amino acid residue in place of a 
glutamic acid (Ingram, 1956). This led into extensive investigation into 
the molecular basis for the disease and the discovery that the gelling of 
the HbS molecules was the basis for sickling of erythrocytes (Singer and 
Singer, 1953 and Allison, 1957). 
The predominant structure of polymerized HbS has been demonstrated to 
be a helical structure with 14 (Dykes et al., 1979) or 16 (Wellems and 
Josephs, 1979) HbS tetramers in each layer. Wishner e^ (1975), using 
X-ray crystallography, defined the intermolecular contact points of the HbS 
molecules (Figure 6). The appearance of the nonpolar side chain of valine 
would not cause any change in the molecule until the Hb was deoxygenated. 
The resultant movement of the 0 chains placed the valine in a position 
favorable to Initiate gelation (Noguchi and Schechter, 1981). The large 
filaments would then inhibit the membrane fluidity of the erythrocyte and 
cause its characteristic sickle-shape, thus inhibiting its ability to pass 
through the narrow capillaries and arteriodes and causing a sickle-cell 
crisis. 
In the past 20 years, numerous therapies have been proposed for the 
treatment of sickle-cell anemia. (For review see Klotz et al., 1981 and 
Chang et al., 1983.) The attempts have focused on two areas: to either 
convalently, or noncovalently, modify the sites necessary for aggregation 
to prevent the sickling, or to shift the conformational equilibrium to 
favor the oxy structure or, better still, to lock the contact regions into 
a conformation unfavorable for aggregation. All of the agents Investigated 
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Figure 6. A model of the arrangement of deoxyhemoglobin S molecules In 
gelated HbS crystal viewed by X-ray diffraction (Each chain is 
shown as a spherical quadrant. Contacts between hemoglobin 
molecules are shown as arrows with the name of the amino acid 
residues and their numbers in the sequence. (From Wishner e^ 
al., 1975)) 
have various pluses and minuses. For example, nitrogen mustard Is an 
extremely effective antl-slckllng agent, yet Is highly toxic. The use of 
aspirin as an acetylatlng agent has also been shown to be effective, yet 
has the ability of acetylatlng other proteins, which may be deleterious. 
Yang (1975) has used peptides analogous to the aggregation site to block 
g 
the necessary g -a chain Interface, Yet these were found to bind to other 
proteins as well and their effects were generally nonspecific. 
A third course of treatment has recently been suggested by Ley e^ al., 
(1983). Using 5-azacytidine, they enhanced the production of HbF in vivo. 
Since the polymerization of HbS is largely dependent on the concentration 
of HbS within the cell (Noguchl and Schechter, 1981), the replacement of 
HbS by HbF resulted in reduced sickling. Unfortunately, the 5-azacytidine 
has been demonstrated to transform cells Im vitro and therefore may cause 
other complications. 
A variation of the hypothesis of Yang (1975) may encompass the good 
points of his work and prevent the nonspecific binding of the peptides. If 
a monoclonal antibody could be Isolated that would selectively bind with 
the g^^Hg-terminal end, as opposed to the g^SfHg-terminal end, or with the 
corresponding aggregation site on other HbS molecules, the active site of 
such an antibody could be synthesized and used as a highly specific 
antlsickling agent. Targeting and fusing of lipid vesicles to the 
erythrocytes with monoclonal antibodies might further enhance specificity 
(Mauk et al., 1980 and Leserman et al., 1980). 
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Goals 
The goals of this project were four-fold: 1) to determine the genetic 
control of the immune response to Hb in inbred mice; 2) to isolate and 
characterize a monoclonal antibody capable of specifically recognizing HbS 
from HbA; 3) to determine the areas on the Hb molecule most likely to be 
antigenic in mice; and 4) to determine the specificities of the monoclonal 
antibodies produced. 
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MATERIALS AND METHODS 
Mice 
All inbred and congenic mice, with the exception of BIO.S, BALB.B and 
BALB.K strains, were obtained from the Jackson Laboratories, Bar Harbor, 
ME. BALB.B mice were obtained from R. Scibienski, University of Califor­
nia, Davis and the BALB.K mice from B. Mishell, University of California, 
Berkeley. BIO.S mice were obtained from C. David, Mayo Clinic, Rochester, 
MN. Studies were carried out using only female mice, 8-20 weeks old at the 
time of immunization. They were housed, 8 per cage, in polycarbonate 
cages, in a day (14 hours) - night (10 hours) cycled room. Cages and 
bedding were changed weekly and following each bleeding. Food and water 
were given ^  libitum. 
Buffers, Solutions and Culture Media 
All formulations of buffers, solutions and culture media used are 
found In Table 4. 
Immunizations 
A solution of either HbAj, or HbS in PBS (phosphate buffered saline, 
pH 7.4) was emulsified, 1:1 (v/v), with complete Freund's Adjuvant (DIFCO 
Laboratories, Detroit, MI) containing 0.5 mg/ml Mycobacterium smegmatis. 
Mice then received an 100 pi aliquot of the emulsion containing the appro­
priate amount of antigen. Hb concentrations were determined by 
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Table 4. Buffers, solutions and culture media 
A. Buffers used in separation of hemoglobins 
1. Huisman procedure (Huisman and Dozy, 1965) 
a. 0.05M Trls HCl pH 8.175 
Trizma base 3.34g 
(Sigma Fine Chemicals, St. Louis, MO) 
Tris HCl 3.54g 
(Sigma) 
ddHgO to m 
b. 0.05M Tris HCl pH 7.6 
Trizma base ].39g 
Tris HCl 6.06g 
ddH^O to IS, 
c. 0.05M Tris HCl pH 7.3 
Trizma base 0.80g 
Tris HCl 6.85g 
ddH^O to U 
d. Phosphate buffered saline (PBS) pH 7.4 
0.003M NaHPO ^H 0 0.45g 
0.007% Na HPOJ olZH 0 2.40g 
0.1311 NaCl ^ 7.40g 
ddH,0 to 11 
?.. Abraham procedure (Abraham et al., 1976) 
a. Stock solution //I; 0.2M glycine, 0.01% KCN 
glycine 15g 
KCN O.lg 
ddHgO to 1 & 
b. Stock solution 2; 0.2M glycine. 0.01% KCN, 0.12n NaCl 
glycine 15g 
KCN O.lg 
NaCl 6.96g 
ddH^O to U 
c. Developing buffers 
Molarity 
of Total 
Developer Developer Solution 1 Solution 2 Volume 
A 0.0024 490 10 500 
B 0.0072 470 30 500 
C 0.0140 440 60 500 
D 0.0240 400 100 500 
E 0.0340 360 140 500 
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Table 4. Continued 
B. Solutions for the separation of the a and 3 subunlts of Hb. 
(Buccl and Frontlcelll, 1965), (Geracl et al., 1969), (Yip et al., 
1972), (Valdes and Ackers, 1977). 
1. Splitting buffer 
a. 0.2M KH„PO 0.5ml 
KH,PO^ 27.2g 
dHgO to U 
b. Saturated NaCl 0.075ml 
NaCl 46.5g 
ddHgO to 100ml 
c. PCMB 2.5ml 
p-chloromecurlc benzoate 50mg 
IM NaOH 4ml 
back titrate with l.OM CH_C00H until the first 
appearance of turbidity. 
ddHgO to 5ml 
2. Phosphate buffers (Williams and Chase, 1968) 
a. Stock solution A (0.5M KBLPO.) 
KH„P0, ^ 68.04g 
EDTA ^ 0.37g 
(Dlsodlum ethylenediamlne tetraacetate) 
ddHgO to 1£ 
b. Stock solution B (0.5M K„HP0,) 
K HPO, ^ ^ 87.09g 
EDTA ^ 0.37g 
ddHgO to 2£ 
c. 0.0IM KHPO - K HPO pH 8.0 
Solution A 1.0ml 
Solution B 19.0ml 
ImM EDTA to Is, 
EDTA 0.37g 
ddHgO to U 
d. 0.02M KHPO - K HPO pH 7.5 
Solution A 6.52ml 
Solution B 33.4ml 
ImM EDTA to l£ 
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Table 4. Continued 
e. O.IM KH PO - K HPO pH 7.0 
Solution ^ 78ml 
Solution B 122ml 
ImM EDTA to 1& 
3. 0.05M Tris HCl pH 8.0 
Trlzma base 6.05g 
IM HCl 26.8ml 
ImM EDTA to 1£ 
4. 0.05M Tris HCl, O.IM 2ME (B-mercaptoethanol) (Sigma) 
Trlzma base 6.05g 
IN HCl 26.8ml 
2ME 7.0ml 
ImM EDTA to l£ 
C. J. Ehrllch - Lettre cells media and solutions 
1. Culture medium 
90% NCTC 135 
(GIBCO, Grand Island, NY) 
10% globulin-free newborn calf serum 
(GIBCO) 
1% antibiotic - antlmycotlc solution 
(GIBCO) 
0.5% Garamycln (10 mg/ml) 
(Scherlng, Kenelworth, NJ) 
2. Hank's balanced salt solution (HBSS) 
(GIBCO Catalogue 1982/83) 
0.0025M CaCl .6H 0 0.28g 
0.0054M KCl 0.40g 
0.0004M KHPO. 0.06g 
0.0005M MgCl .6H 0 O.lOg 
0.0006M MgS0'.7H,0 O.lOg 
0.1369M NaCr 8.00g 
0.0042M NaHCG 0.35g 
0.0055M Glucose l.OOg 
phenol red O.Olg 
distilled H^O to 1000ml 
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Table 4. Continued 
3. 2% Trypsin solution 
Trypsin (100,000 unlts/mg) 0.50g 
(GIBCO) 
HBSS to 25ml 
D. Hemoglobin electrophoresis buffers and solutions (Rlggs, 1981) 
1. Electrode buffers 
a. Upper chamber buffer pH 8.9 
Trlzma base 6.32g 
glycine 3.94g 
ddHgO to U 
b. Lower chamber buffer pH 8.1 
Trlzma base 36.30g 
IN HCl 150.0ml 
dH^O to 3i  
2. Acrylamlde solutions 
a. acrylamlde stock solution 30% 
acrylamlde 30gm 
(BloRad Laboratories, Richmond, CA) 
ddHgO to 100ml 
b. bisacrylamide stock solution 1% 
blsacrylamlde Igm 
(BloRad Laboratories) 
ddHgO to 100ml 
3. Buffers and solutions for polyacrylamlde solutions 
a. Separating gel 
1. Separating gel buffer pH 8.9 7.5ml 
Trlzma base 18.15g 
IN HCl 24.0ml 
TEMED 0.4ml 
(N,N,N',N'-tetramethylethlene dlamlde) (BloRad) 
ddHgO to 100ml 
2. Acrylamlde stock solution 7.5ml 
3. bisacrylamide stock solution 6.0ml 
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Table 4. Continued 
4. ddHgO 8.7ml 
5. Ammonium Persulphate 
APS (BioRad Laboratories) 
ddHgO to 
0.3ml 
0.228g 
10ml 
b. Stacking gel 
1. Stacking gel buffer pH 7.2 
Trizma base 
IM H.PO, 
TEMED 
2.0ml 
2.85g 
12.8ml 
0.1ml 
2. Acrylamide stock solution 1.0ml 
3. bisacrylamide stock solution 0.8ml 
4. ddHgO 6.1ml 
5. ammonium persulphate 0.1ml 
4. Sample buffer pH 8.1 
upper chamber buffer 
2-mercaptoethanol (BioRad) 
bromphenol blue 
93ml 
7ml 
0. Igm 
5. Staining solution 
methanol 
glacial acetic acid 
Coomassie Brillant Blue R250 
(BioRad) 
ddHgO to 
40ml 
7ml 
Ig 
100ml 
6. Destaining solution 
same as the staining solution without the 
Coomassie Brillant Blue R250. 
7. Aqueous isobutanol 
isobutanol 25ml 
ddH G 25ml 
shaRen well and allowed to equilibrate in 
tightly closed bottle. 
Table 4. Continued 
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E. Solutions for affinity chromatography 
1. coating buffer pH 8.0 
NaHCO 8.4g 
NaCl 29.2g 
dHgO U 
2. blocking buffer pH 8.0 
Ethanolamlne 6ml 
dHgO to 100ml 
3. acetate buffer pH 4.0 
NaC H 0 8.2g 
NaCI ^ 29.2g 
glacial acetic acid 3.5ml 
ddH 0 to IZ  
adjust to pH 4.0 with IM CH^CCOH 
4. IM CH COOH 
glacial acetic acid 38.8ml 
ddHgO to IZ 
F.  Lowry solutions (Garvey et al.» 1977) 
1. Reagent A 
2. Reagent B 
CuSO,.5H,0 
ddHgO to'' 
3. Reagent C 
Na CO 
O.TN NaOH to 
2.0g 
lOOml 
l.Og 
100ml 
20.Og 
U 
Mix 1 part A + 1 part B + 100 parts C (stable for 5 hours) 
4. Folin Reagent 
2 N phenol 
(Fisher Scientific Company, Fair Lawn, NJ) 
Dilute 1 to 2 with distilled HO 
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Table 4. Continued 
5. Protein standards 
a. mouse y-globulin Img/ml 
mouse Y-globulln lOmg 
(Sigma) 
ddH^O to 10ml 
b. bovine hemoglobin 
bovine Hb lOmg 
(Sigma) 
ddHgO to lOml 
G. Solution and buffers for ELISA (Voiler ^  , 1978) 
1. Carbonate - bicarbonate coating buffer 
Na CO 1.59g 
NaHCO^ 2.93g 
NaN ^ 0.20g 
ddHp to U 
2. Blocking agent (2% BSA) 
30% bovine serum albumin 6.67ml 
(Sigma) 
coating buffer 93.3ml 
3. PBS-tween 20 
NaCl 160.0g 
Na^HPO..12H,0 58.Og 
KCÎ 4.0g 
KH PC, 4.0g 
Twéen 20 10.Oral 
(Sigma) 
ddH^O to 20£ 
4. Substrate solution (Img/ml p-nitrophenyl phosphate) 
a. Substrate buffer 
dlethanolamine 97ml 
MgCl lOOyg 
ddH-O to 800ml 
adjust pH to 9.8 with IN HCl 
ddHgO to 1£ 
b. Substrate 
"Sigma 104" phosphatase substrate 
(Sigma) 
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Table 4. Continued 
5. 3N NaOH 
NaOH 120g 
ddHO to 1& 
H. Culture media for monoclonal antibodies 
1. Dulbecco's modified Eagle's medium (DME) 
a. Dulbecco's modified Eagle's medium 425ml 
(GIBCO) 
b. Fetal bovine serum (FBS) 75ml 
(Sterile Systems, Logan, UT) 
c. 100 X antibiotic-antimycotlc solution 5ml 
(10,000 units/ml penicillin base) 
(10,000 mcg/ml streptomycin base) 
(25 mcg/ml Fungizone [GIBCO]) 
d. lOmg/ml garamycin sulphate 2.5ml 
(Schering) 
e. 200mM glutamine 5ml 
(GIBCO) 
2. HBlOl serum-free medium 
a. HBlOl serum-free medium 500ml 
(Hana Biologicals, Berkeley, CA) 
b. HBlOl supplement 5ml 
(Hana Biologicals) 
c. Sodium pyruvate (lOOmM) 5ml 
sodium pyruvate l.lg 
ddH 0 to IGOml 
filter through 0.22iiM Millipore filter 
d. 200mM glutamine 5ml 
e. 100 X antlbiotic/antimycotic 5ml 
f. lOmg/ml garamycin sulphate 2.5ml 
42 
Table 4. Continued 
3. RPMI 1640 medium 
a. RPMI 1640 medium 450ml 
(GIBCO) 
b. Fetal bovine serum 50ml 
c. 200mM glutamlne 5ml 
d. 100 X antlblotlc/antlmycotlc 5ml 
e. lOmg/ml garamycln sulphate 25ml 
4. Freezing medium 
a. DME 70ml 
b. 10% dimethyl sulfoxide (DMSO) 10ml 
c. FBS 5ml 
(final FBS concentration, 20%) 
5. Methionine deficient RPMI 1640 and HBlOl media were obtained from 
GIBCO and Hana Media, Inc., respectively. The HBlOl was already 
prepared, the RPMI 1640 came as a "select amine" kit. To prepare 
the RPMI 1640 (-) medium, it was necessary to mix all the pre-
measured vials together, excluding the amino acid the medium was 
to be deficient in. 
I. Solutions and buffers for SDS-PAGE (Haas and Kennett, 1980) 
1. Separating gel buffer pH 8.9 
Trizma base 36.3gm 
IM HCl 48.0ml 
ddH^O to 100ml 
2. Stacking gel buffer pH 6.7 
Trizma base 5.7g 
IM H PO, 25.6ml 
ddHgO to 100ml 
3. Sample buffer (2x) 
Trizma base 7.57g 
glycerol 100.Og 
SDS 23.Og 
B-mercaptoethanol 50.0ml 
Coomassie Brillant Blue R250 l.Ogm 
ddH^O to 500ml 
43 
Table 4. Continued 
4. Electrode buffer 
Trizma base 6.0g 
Glycine 28.8g 
SDS (20%) 10.0ml 
J. Solutions for autoradiography 
1. S-methionine ImCi/ml 
Activity of ^^S-methionine (A)^ = 5mCi(e 
where e = natural logarithm 
y = decay constant = 0.007891d (Wang ^  al., 1975) 
t = time (d) since initial activity measured 
35 Vo 
ml of S-methionine = (^) (c^) (V^) 
where Vg = volume of ^^S-methionine 
A(- = activity of at time t 
Cp = final concentration of ^^S desired 
Vip = final Volume of Cp 
2. Toluene Fluor 
PPG (2,5 Diphenyloxazole) 18.6g 
(Fisher) 
POPOP (P-bls-[2-(5-phenyloxazolyl)]-benzen 0.94g 
(Fisher) 
add to 1 gallon toluene 
3. Kodak GBX Developer 
(Eastman Kodak Company, Rochester, NY) 
Developer 760ml 
ddHgO to 3.8% 
4. Kodak GBX fixer 
fixer 760ml 
ddHgO to 3.8% 
5. stop bath 3.5% (v/v) CHLCOOH 
Glacial acetic acid 14ml 
ddHgO to 4& 
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absorbance at 540 nm using a Gilford 250 spectrophotometer (Gilford Instru­
ments, Oberlln, OH) (e= 14.3 x 10 ^cm (Rlggs, 1981). The emulsion 
was distributed equally In the hind footpads using a 3 ml syringe equipped 
with a 5/8" 30 gauge needle (Becton Dickinson and Company, Rutherford, NJ). 
Twenty-one days later, mice were boosted, intraperitoneally (i.p.), with 
the same dose of antigen in phosphate-buffered saline (PBS). Seven days 
subsequent to the final boost, mice were bled from the orbital venous sinus 
and the blood collected in 400 yl microfuge tubes (Beckman Instruments, 
Palo Alto, CA). The blood was allowed to clot for 1 hour at room tempera­
ture and was stored at 4°C overnight. The next morning, the clot was 
removed using a wooden applicator stick and the tubes were centrlfuged at 
12,000 g, for 5 minutes, in a Microfuge 12 centrifuge (Beckman Instru­
ments). The serum was transferred to clean 400 yl tubes and stored at 
-70°C until used. 
Production of Polyclonal Ascitic Fluid 
Ehrllch's-Lettre ascites cells were obtained from the American Type 
Culture Collection (Rockvllle, MD). The cells were cultured according to 
the method of Boone et al., (1965). Ascites cells, at a concentration of 
5 2 2.5 X 10 cells/ml, were cultured in 25cm Corning tissue culture flasks, 
(Fisher, Chicago, IL) in 10-12 ml of NCTC 135 medium (GIBCO, Grand Island, 
NY) supplemented with 10% Gamma-Globulin free newborn calf serum (GIBCO), 
0.5% Garamycln (Schering, Kenworth, NY) and 1% antimycotlc-antlbiotlc 
solution (GIBCO). Cells were Incubated at 37*C in a 5% CO^ humid atmos­
phere. The medium was changed every 3-4 days until the cells became 
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confluent, after which they were dislodged with 0.2% trypsin (GIBCO) in 
Hank's balanced salt solution (HESS) (GIBCO), counted and 1 x 10^ cells 
inoculated into fresh flasks and medium. Cells were passaged from cell 
culture to the mouse by first treating them as above and washing them once 
in fresh medium. Between 1.5 and 2.0 x 10^ cells in 0.2 ml of culture 
medium were inoculated concomitantly, ip, with 20 y g of either HbA^ or HbS 
in a 0.2 ml volume into DBA/2 mice previously hyperimmunized against the 
appropriate antigen. Mice were watched for tumor formation beginning 7 
days after injection and every day thereafter. Ascites fluid was tapped 
aseptically, 7-14 days subsequent to tumor appearance, with a lOcc syringe 
equipped with an 18 gauge needle. The needle had six holes perforated 
along its barrel within 2 cm of the beveled end of the needle. Usually, 
5-lOml of ascites fluid were collected. The fluid was transferred to a 
15 ml centrifuge tube and centrifuged at 1000 g for 10 minutes at room 
temperature. The clear ascites fluid was collected, filtered through a 
0.22 pm Millipore filter, aliquoted into 0.5ml fractions and stored at 
-20°C until used. 
Hemoglobin Purification 
Hemoglobins 
Samples of sickle-cell trait (AS) or sickle-cell-C (SC) whole blood 
were obtained from anonymous donors through the Hemoglobin Clinic, Michael 
Reese Hospital, Chicago, IL. Hbs E, N Baltimore and Russ, were the kind 
gift of Dr. Jerry Wilson, Medical College of Georgia, Augusta, GA. Hbs 
Beograd, F, A^, G-Georgia and Montgomery were obtained from ISOLABS, Inc., 
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Akron, OH. HbS, C-Harlem, D-Iran, D-LA, G-Phlladelphia, N-Seattle, 
0-Indonesla, Q-Indla, Arya, Hasharon, Hopkins II, Korle-Bu and Zurich were 
received as heterozygous hemolysates from Dr. Winston Moo Penn at the 
Center for Disease Control, Atlanta, GA and were subsequently purified in 
our laboratory. 
Isolation of hemoglobin from whole blood 
Whole blood was collected in Femoral Blood Packs (Traveno] Laborato­
ries, Morton Grove, IL) containing a citrate phosphate, dextrose, adenine 
anticoagulant solution. Erythrocytes were isolated by centrifugation of 
the blood for 10 minutes at 500 g at room temperature (Beckman TJ-6 Centri­
fuge, Beckman Instruments). After discarding the supernatant, the red cell 
pellet was washed 4 times in PBS. After each wash and subsequent centrl­
fugation, care was taken to remove the buffy coat layer of cells that would 
form above the red cell pellet. This removed greater than 99% of the 
lymphocytes. 
After the final wash, the erythrocytes were lysed by the addition of 
50ml of sterile deionized-distilled H^O (ddH^O). Cellular debris were 
removed by centrifugation at 20,000 g for 30 minutes at 4°C (Beckman J-21B 
centrifuge). The Hb solution was transferred to clean centrifuge tubes and 
spun again at 20,000 g for 30 minutes. After carefully decanting the 
clarified Hb, it was converted into CHb (carbomonoxyhemoglobin) by bubbling 
CO (Mathison Gas Company, Joliet, IL) through the solution at 5 psi for 10 
minutes. The CHb was then filtered through at 0.22 pm Millipore filter and 
aliquoted into 2 ml freezer vials (GIBCO, Grand Island, NY) and stored in 
liquid Ng until used. 
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Purification of individual hemoglobins 
Hemoglobins were purified by ion exchange chromatography using one of 
two methods. For Hbs, HbS, HbA^ and HbC, the procedure of Huisman and Dozy 
(1965) was followed with a few modifications. Purification of the hemoly-
satGs obtained from the Center for Disease Control, was done using a 
modification of the glycine-KGN system developed by Abraham et al., (1976). 
The procedure of Huisman and Dozy (1965) was to use a decreasing 
linear pH gradient and DEAE-cellulose to achieve separation. The modifica­
tions used involved substituting DEAE-Sephacel (Pharmacia Fine Chemicals, 
Piscataway, NJ) in place of the DEAE-cellulose and a slightly lower start­
ing pH (described below). DEAE-Sephacel, a beaded cellulose anion ex­
changer, replaced the DEAE-cellulose since it was much more homogeneous 
than the fibrous cellulose and therefore packed more uniformly. This also 
allowed for greater flow rates to be used with little decrease in the bed 
volume and peak resolution. 
The Sephacel was prepared by filtering approximately 300 ml of the 
prepared slurry through Whatman #1 filter paper, 9 cm in diameter, using a 
Buchler funnel and 2 liter filter flask attached to an aspirator. After 
the gel had separated from the sides of the funnel, the gel was removed by 
inverting the funnel and gently tapping it against the bench top. The 
filter paper was removed and the gel immersed into 400 ml of the 
appropriate buffer, in this case, 0.05 M Tris-HCl pH 8.175. The gel was 
stirred with a glass rod, allowed to settle for 5 minutes, resuspended by 
stirring and filtered again. This operation was repeated until the pH of 
the effluent matched that of the starting buffer. The gel was then 
resuspended in 400 ml of starting buffer. 
48 
After the gel had been equilibrated. It was packed. In a single step, 
in a 1.9 cm x 50 cm glass column (Bio Rad Laboratories, Richmond, CA), 
equipped with a 250 ml conical reservoir. The initial 3 cm of the column 
was packed by gravity, with the stopcock closed. The stopcock was then 
opened and the column allowed to pack at a flow rate of 30 ml/hour. After 
packing, 1 ml of hemoglobin (100 mg/ml) was diluted with an equal volume of 
0.1 M Tris-HCl (pH 8.175) and applied to the column. A linear pH gradient 
(8.175 — 7.6) of 0.05 M Tris HCl was used to elute the hemoglobins. The 
gradient was formed by a Pharmacia gradient mixer using 250 ml of 0.05 M 
Tris HCl, pH 8.175, in the forward chamber, and 250 ml of 0.05 M Tris HCl, 
pH 7.6 in the rear chamber. The flow rate was 30 ml/hour and 6 ml 
fractions were collected using a LKB Redirac (LKB-Produkter, Bromma, 
Sweden). When the gradient was completed, any further hemoglobin remaining 
on the column was eluted by changing the buffer to 0.05 M Tris-HCl pH 7.3. 
Fractions were checked for their absorbance at 540 nm using a Gilford 250 
spectrophotometer. Hb containing solutions were treated with carbon 
monoxide as above, dlalyzed overnight against PBS, filtered through a 
0.22 urn Millipore filter and stored in 2,0 ml freezer vials in liquid 
The procedure of Abraham et al., (1979) was modified slightly in that 
DEAE-Sephacel was used in place of DEAE cellulose. 300 ml of Sephacel was 
prepared as described above, with the starting buffer being 0.2 M glycine -
0.01% KCN. The pH of this solution varied between 7.7 and 7.9 and was not 
adjusted. The amount of buffer needed to equilibrate the Sephacel was 
found to be at least 4 times the amount needed when the Tris-HCl buffer was 
used. Three hemoglobins were purified at the same time using three sepa­
rate 19 x 18 cm econo-columns (Bio-Rad Laboratories). The individual 
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columns were packed to a height of 15 cm. Hemolysates, approximately 
0.3 ml In volume, were diluted with an equal volume of 0.4 M glycine -
0.02% KCN and then applied to the column. The hemoglobins were eluted from 
the column using a stepwise gradient of increasing ionic strength. The 
initial elution was done with the starting buffer, 0.2 M glycine, 0.01% 
KCN. Subsequent eluting buffers were prepared by mixing the starting 
buffer with various volumes of an Identical buffer containing 0.12 M NaCl, 
sufficient to give final molarities of NaCl equal to 0.0024, 0.0072, 0.014, 
0.024 and 0.034. Since each hemoglobin of interest would elute at a 
different ionic strength, the number and sequence of eluting buffers used 
depended on the hemoglobin of Interest (Table 5). After each Hb of 
interest was eluted, the rest of the Hb was eluted from the column using 
the highest ionic strength buffer. The flow rate of the columns was set at 
30 ml/hour. Six ml fractions were collected by hand in 13 x 100 mm 
borosilicate tubes and their determined. Those fractions containing 
the correct Hb were pooled and the solution concentrated to a volume of 3-5 
ml. Carbon monoxide was again bubbled through the samples after which the 
samples were stored at 4''C in tightly closed 5 ml vials flushed with CO. 
Isolation of and ^  subunlts from hemoglobin 
The traditional procedure to Isolate the a and g chain subunlts of 
hemoglobin has been described by Buccl and Frontlcelll (1965). In this 
method, the chains are split using an excess of PCMB (p-chloro-mercurlc 
benzoate) and then separated by passage over a carboxy methyl-cellulose 
column. Unfortunately, this procedure is very deleterious to the a-subunit 
and yields are low (Geraci et al., 1969). Therefore, initial efforts at 
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Table 5. Sequence of buffers for Hb variant elutlon 
Hemoglobin % Hemolysate* Eluted Buffers (ml)^ 
HBT 16-35 after HbA^ C(75),D(60),E(60) 
D-LA 38 between Aj^ & Ag B(75),C(60),E(60) 
0-Indonesla 10% directly after Ag Bf75),C(48),E(60) 
Q-India 20 just before HbAj^ B(100),C(75),D(75),E(60) 
J-Baltimore 40-50 after HbAj C(75),D(60),E(60) 
Korle-Bu 30-40% as HbS B(75),C(60),Ef60) 
C-Harlem 40 between HbA^ & A^ B('75),G(60),E(60) 
Hasharon 14-21 between HbA^ & Ag B(75),CC60),E(60) 
Arya 22 between HbA^ & A^, B(75),C(60),E(60) 
G-Philadelphla 33-45 just before HbA^ Bfl00),C(75),E(60) 
D-Iran 40 as HbS B(75),Cf60),E(60) 
Hopkins II 17-27 after HbA^ Cf75),D(60),E(60) 
N-Seattle 50% directly after HbA^ C(100),D(75),E(60) 
^ As estimated by Lehmann and Kynoch, (1976). 
^ Volumes are approximate (±5 ml) since separation was usually 
monitored visually. 
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using this procedure were discontinued. 
The method used In this work was a combination of modifications 
suggested by Geracl et , (1969), Valdes and Ackers (1977) and Yip et al., 
(1972), of the original Bucci and Fronticelll protocol, with the added 
modification of using DEAE-Sephacel as the ion exchange matrix. To 5 ml of 
a 1% solution of either carbomonoxy-HbA^, or HbS, 0.5 ml of 0.2 M monobasic 
potassium phosphate, and 0.075 ml of saturated NaCl were added. Sepa­
rately, 50 mg of PCMB were dissolved in a minimal volume (i.e., 5 ml) of 1 
M NaOH. The solution was then back titrated with 1 M CH^COOH, until 
turbidity appeared and remained. An 8-fold molar excess of PCMB was then 
mixed rapidly with the hemoglobin solution. The pH of this solution should 
be approximately 7.0. A pH higher than 7.0 Indicates poor back titration 
of the PCMB and the solution should be discarded. 
The Hb-PCMB mixture was titrated with 1 M CH^COGH to pH 5.4 and kept 
at 4*C, undisturbed, overnight. A precipitate formed and was discarded 
after centrifugation at 2000 rpm for 10 minutes at room temperature (TJ-6 
Centrifuge, Beckman Instruments). 
The solution was then passed through a 2.0 x 50.0 cm G-25 Sephadex 
column (Sigma) previously equilibrated with 0.01 M phosphate, 0.001 M EDTA 
buffer, pH 8.0 (Yip e^ ^ ., 1972), to remove the separated chains from the 
presence of PCMB and to equilibrate them with the buffer needed for purifi­
cation. 
A 3.0 X 15.0 cm column of DEAE-Sephacel, equilibrated with the same 
buffer as the G-25 Sephadex column, was prepared, the a-chaln-6-chain 
solution was added to it and eluted with the equilibrating buffer. The a-
chalns were eluted in a broad peak soon after the void volume. To separate 
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unspllt Hb from the 3 chains, the buffer was changed to 0.02M phosphate, 
0.001 M EDTA, pH 7.5 (Geraci et al., 1969), following which the g chains 
were eluted with 0.1 M phosphate, 0.001 M EDTA, pH 7.0. The inclusion of 
0.001 M EDTA in all buffers is important to keep the carbomonoxy-herae from 
becoming met-heme (Yip ^  al., 1972). Fractions were 6 ml in volume and 
the flow rate was 30 ml/hour. 
After the chains had been separated, it was necessary to remove the 
PCMB from the SH groups in the molecule. This was accomplished using the 
procedure of Valdes and Ackers (1977). The a- and 3-chain containing 
solutions were again passed through a 2.0 x 50 cm G-25 sephadex column, 
this time equilibrated with 0.05 M Tris-HCl, 0.001 M EDTA pH 8.0. Two 
additional columns of G-25 sephadex were prepared and equilibrated with the 
Tris-HCIEDTA buffer. The volumes of the two solutions containing the a-
and 3chains were determined and an equal volume of 0.05 M Tris-HCl, 0.001 M 
EDTA, 0.1 M 2-mercaptoethanol (2-ME), allowed to flow into each column. 
The a- and 3-chain solutions were then added to the columns and eluted with 
0.05 M Tris-HCl, 0.001 M EDTA. Removal of Hg was determined by measuring 
the absorbance of the a and 3 chain at 250 and 280 nm and comparing the A 
250/280 ratio with known values (Winterhalter and Colosimo, 1971). 
Purified chains were stored in tightly closed vials, at 4°C, after being 
treated with CO as previously described. They were checked for purity by 
polyacrylamide gel electrophoresis (PAGE). 
Preparation of 3-chain N-terminal octapeptides 
The sequences of the octapeptides used in this work are found in Table 
6. Three of the peptides are homologous to the 3 chain, N-terminal 
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Table 6. Sequence of the octapeptides synthesized compared to the 
NH -terminal octapeptide of the g-chain of B10,D2 mouse lib 
(Fasman, 1976) 
Residue # 
Hemoglobin 1 2 3 4 5 6 7 8 
Human 3^1 val his leu thr pro glu glu lys 
Human S 3 val his leu thr pro val glu lys 
MA, 
3 1 val his leu thr asp glu glu lys 
MS 
3 val his leu thr asp val glu lys 
Mouse Kb val his leu thr asp ala glu lys 
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octapeptldes of HbA^, HbS and B10.D2 mouse Hb. The B10.D2 mouse Hb was 
used since It does not have the minor Hb band found in some other mouse 
strains. The remaining two are similar to the mouse peptide, but with the 
substitution of either a glutamic acid or valine residue in the sixth 
position. 
The peptides were prepared by Mr. William Harris, Department of 
Biochemistry and Biophysics, Iowa State University, Ames, lA. A solid 
phase synthesis was used (Beckman model 990 Peptide Synthesizer, Beckman 
Instruments) and purification obtained by HPLC (high pressure liquid 
chromatography) using an Altex ultrasphere column. Peptide composition 
(Table 7) was determined using a Durrum D-400 amino acid analyser (Durrum 
Instruments, Sunnyvale, CA). 
Polyacrylamide gel electrophoresis (PAGE) of hemoglobins 
PAGE of the numerous variants of hemoglobin was accomplished using a 
discontinuous buffer system described by Riggs (1981). A 7.5% T, 2.67% C 
separating gel (140 x 160 mm) was prepared by combining 7.5 ml of a 30% 
acrylamide stock solution (BRL, Bethesda, MD) 6 ml of a 1% bis-acrylamide 
stock solution, 7.5 ml of the separating buffer (1.5 m Tris-HCl, 0.4% 
TEMED, pH 8.9) and 8.7 ml of distilled and deionized HgO, in a 125 ml 
Erlenmeyer vacuum flask. The solution was degassed, using an aspirator 
hooked up to a laboratory faucet, for at least 10 minutes with constant 
agitation, following which 0.3 ml of 1 mM ammonium persulphate (APS) was 
added and the solution immediately transferred to a 30 ml plastic syringe 
equipped with a 20 gauge 5" needle. 
Two different types of electrophoresis cells were used throughout this 
Table 7. Amino acid analysis of 6^, 3^1 and 3^^ peptides 
3^1 3^ 3^1 3^^ 
Amino Expected Observed Expected Observed Expected Observed Expected Observed 
Acid Mole % Mole % Mole % Mole % Mole % Mole % Mole % Mole % 
val 12.5 11.9 25.0 23.2 12.5 11.8 25.0 23.9 
his 12.5 11.8 12.5 12.3 12.5 11.1 12.5 11.9 
leu 12.5 12.7 12.5 12.8 12.5 12.8 12.5 12.7 
thr 12.5 12.0 12.5 12.9 12.5 12.5 12.5 12.1 
pro 12.5 11.4 12.5 13.2 0.0 0.0 0.0 0.0 
glu 25.0 26.7 12.5 12.8 25.0 25.6 12.5 12.9 
lys 12.5 13.4 12.5 12.8 12.5 12.9 12.5 12.6 
asp 0.0 0.0 0.0 0.0 12.5 13.3 12.5 12.9 
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work. The BloRad Dual Vertical Slab gel electrophoresis cell, (Bio-Rad 
Laboratories, Richmond, CA) used gels measuring 140 x 140 mm. The newer 
system, the Protean Dual Vertical Slab Gel electrophoresis cell (BloRad), 
used gels measuring 140 x 160 mm. Gels 1.5 mm thick were poured by using 
the 30 ml syringe to carefully Inject the solution between vertical glass 
plates separated by 2 - 1.5 x 15 x 160 mm dividers. Occasionally, a gel 
backing called Gel Bond PAG (FMC Corporation, Rockland, MD) was used to 
facilitate handling of the gel. The solution was poured to 30 mm below the 
top of the plate. After removing the syringe and immediately rinsing it 
with ddH^O, the gel was overlayered with about 1 ml of aqueous Isobutanol. 
This allowed a flat and even surface to be formed. 
While waiting for the separating gel to polymerize, the stacking gel 
(3% T, 2.67% C) was prepared. 1.0 ml of acrylamide stock, 0.8 ml of bis-
acrylamide stock, 2.5 ml of stacking buffer (0.24 m Tris-PO^, 0.1% TEMED 
[v/v], pH 7.2) and 6.1 ml of ddHgO, were added together in another 125 ml 
Erlenmeyer filter flask. The solution was deaerated for at least 20 
minutes. After the separating gel polymerized, the Isobutanol was removed 
by a 9" pasteur pipette and the gel top washed by 4-5 ml of ddH^O. A 
teflon comb, containing either 10 or 15 prongs, was inserted until the 
bottoms of the prongs were 1cm above the separating gel. The stacking gel 
solution was then removed from the vacuum, 0.1 ml of 1 mM APS added, and 
the solution applied to the top of the separating gel, care being taken to 
prevent air bubbles from attaching to the bottom of the prongs. The gel 
was then allowed to polymerize for 1 hour. 
Samples were prepared for electrophoresis by first adjusting their 
concentrations to 1.0 mg Hb/ml with ddHgO (e^^Q = 1.43 x 10M~^ cm ^) 
57 
(Fasman, 1976). One hundred yl of each hemoglobin were then mixed with 
100 ul of sample buffer (stacking gel buffer with 0.1 M 2-ME diluted 1:2 
with glycerol). The lower buffer chamber was filled with 3£ of 0.1 M 
Tris-HCl, pH 8.1 and the upper chamber with 500 ml of 0.0052 M 
Tris-glycine, pH 8.9, with 0.01% (w/v) Bromophenol Blue. Electrophoresis 
was carried out at 4°C for 2-3 hours or until the tracking dye was 1-2 cm 
from the bottom of the gel. Three watts of power were applied to the gel 
using either a Buchler 3-1500 power supply (Buchler Instruments, Fort Lee, 
NJ) or a BioRad 1420B power supply. 
Gels were stained overnight using a 40% (v/v) methanol, 7% (v/v) 
acetic acid and 1% Coomassie Brillent Blue R250 stain and destained using 
the methanol/acetic acid/water solution without the dye. Gels were stored 
in Saran Wrap at 4°C. 
Quantitation of Anti-Hb Serum Antibody 
Affinity chromatography and quantitation of anti-Hb standard 
One gram of CNBr-activated Sepharose (Pharmacia) was swollen in 1 mM 
HCl for 2 hours. The gel was then poured into a coarse sintered glass 
filter and washed with one 5 ml volume of coating buffer (0.1 M NaHCO^, 0.5 
M NaCl pH 8.0), resuspended in an additional 5 ml of coating buffer and 
transferred to a 15 ml centrifuge tube (Corning Glass Works, Corning, NY). 
Immediately, 10 mg of either HbA^, or HbS, dissolved in coating buffer to a 
concentration of 1 mg/ml, was added to the tube and the mixture incubated 
overnight at 4°C on a slowly revolving rotator (8 rpm). The next morning, 
the Hb-sepharose was centrifuged at 50 g for 30 seconds, the supernatant 
removed and its Ag^^ determined. The efficiency of coupling was normally 
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greater than 95%. Excess reactive groups were blocked by the addition of 
1 M ethanolamine (pH 8.0) followed by incubation for 2 hours at room 
temperature with constant mixing. The Hb-sepharose was then washed with 
alternately high (coating buffer, pH 8.0) and low (0.1 M sodium 
acetate-acetate, 0.5 M NaCl, pH 4.0) pH buffers, 500 ml/g sepharose, to 
remove any loosely bound Hb. The gel was then packed in a 0.9 cm x 10 cm 
glass column (BioRad) to give a total bed volume of 3 ml. Before sample 
application, the column was washed with 5 ml of eluting buffer, (1.0 M 
acetic acid, 0.5 M NaCl, pH 2.5). This removed any Hb not strongly bound 
to the sepharose that could have been released when the anti-Hb antibody 
was eluted. After re-equilibrating the column with coating buffer, a 
300 yl aliquot of the y-globulin fraction of either DBA/2 anti-HbS serum or 
DBA/2 anti-HbA^ ascites fluid was applied to the top of the appropriate 
column and then incubated for 15 minutes. The column was then washed with 
the high pH buffer until the was less than 0.002. Specific antibody 
was eluted by the IM CH^COGH, 0.5 M NaCl buffer. It was observed that 99% 
of the antibody was recovered in the first 3 ml fraction. This fraction 
was neutralized with 1.0 M NaOH and its protein concentration determined by 
the procedure of Lowry et al., (1951). 
The Lowry method of determining the concentration of a protein 
solution has been well characterized in many texts of biochemistry. The 
overall procedure followed is that presented in Garvey et al., (1977). 
Samples, standards, and blanks were prepared to give a final volume of 1.2 
ml of solution, then 4 ml of solution #1 (0.027% Na-tartrate, 0.01% CuSO^'5 
HgO, 2% NagCOg in 0.1 M NaCl) were added to samples, standards and blanks. 
The initial concentration of the standard used for Ig determination was a 
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solution of 100 yg/ml of mouse Y globulin. When Hb protein determinations 
were made, 100 pg/ml of bovine hemoglobin was the standard protein 
solution. The test tubes were vortexed, then were allowed to stand for 10 
minutes. Folin reagent (2N Phenol) (Fisher) was diluted to 1 N and 0.4 ml 
added to all tubes, which were vortexed and allowed to stand for 30 minutes 
before absorbance was read at 750 nm. Protein concentrations of the 
samples were then extrapolated from the standard curve. 
Enzyme-linked Immunosorbant Assay (ELISA) 
In order to determine the amount of actual antl-Hb antibody produced 
by each strain of mouse, an enzyme-linked Immunosorbant assay was devel­
oped. This assay was easier, faster, less expensive and substantially 
safer than radioimmunoassays. The procedure Involved coupling an antigen 
to a solid support, incubating the unknown serum sample with the antigen, 
washing out nonbound antibody and then adding a second antibody coupled to 
an enzyme. Enzyme substrate was then added and the amount of substrate 
converted to product was measured, giving a relative measure of antibody 
present. 
The micro-ELISA procedure of Voiler et , (1978), based on the 
original method of Engvall and Perlman (1971) was the basis for the two 
different types of ELISA used. For the work involving the genetic control 
of the immune response. Voiler's indirect ELISA was used. In the 
monoclonal antibody work, a more sensitive assay was needed and the 
indirect assay was modified accordingly. 
The Indirect ELISA was carried out in 96-well round bottom substrate 
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plates (Cat if 011-010-3150 or 011-010-3650, Dynatech Laboratories, Alexan­
dria, VA). Antigen was electrostatically attached to the polystyrene 
plates by using a 0.1 M sodium carbonate-bicarbonate buffer (pH 9.6). 
The antigen solution was allquoted, in 200 yl quantities, into each well of 
the 96 well plate, which was then incubated at for 24 hours in a humid 
atmosphere. The plates were then shaken out and flooded with a PBS-tween 
20 (PBS-20) wash solution, pH 7.4, and allowed to sit for at least 3 
minutes. This procedure was repeated twice. The wells were then filled 
with 100 ul of PBS-20 using an 8-channel multlpipettor (Flow Laboratories, 
Rockville, MD). Serum or ascites fluid samples were diluted to the correct 
concentration in PBS-20 and 100 yl quantities were pipetted, in duplicate, 
into the appropriate wells in the 1st or 7th columns. Samples were then 
serially diluted 6-fold using the multlplpetter. Six serum samples were 
tested per plate along with either a known amount of anti-hemoglobin 
antibody or a given amount of monoclonal antibody specific for the N-
terminal 3-chain octapeptldes. Plates were incubated for 2 hours at room 
temperature, and then washed as above. Rabbit anti-mouse Y-globulln 
coupled to alkaline phosphatase (R-xMGG-AP) was either prepared in our 
laboratory or purchased from Sigma (St. Louis, MO). Usually, the R-xMGG-AP 
was used at a 1:1000 dilution in PBS-20. After a second incubation of 2 
hours at room temperature the plates were again washed as above. A 1 mg/ml 
solution of p-nitrophenyl phenol (PNPP) (Sigma) was prepared in a 10% 
solution of dlethanolamlne, pH 9.8, and 200 yl allquoted Into each well. 
The color was allowed to develop for 60 minutes, after which the reaction 
was stopped with 100 pi of 3 M NaOH. This was just enough solution to fill 
the wells of the microtiter plate and to form a meniscus over the wells. 
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Any volume less than this was usually not sufficient to adequately fill the 
semi-automated microcuvette. The absorbance at 400 nm was then determined 
using the microcuvette and a Gilford 250 spectrophotometer equipped with a 
digital printer. The amount (yg/ml) of anti-Hb antibody present in the 
serum samples was determined by comparing each sample curve with the 
standard curve. Relative amounts of antl-peptide antibody were also 
determined. By having a standard curve present in each plate, the experi­
mental error caused by day to day variation in parameters such as room 
temperature, different plate lots, etc., was greatly diminished. 
After the majority of the data on the immune response had been col­
lected, work began on the production of monoclonal antibodies. As will be 
discussed later, it was necessary to enhance the sensitivity of the EI,ISA 
assay to effectively screen for positive clones. This Improved ELISA was 
also used when determining the reactivity of the monoclonal antibodies to 
the numerous Hb variants. 
In order to increase the sensitivity of the assay, several modifica­
tions were done. 
The first change was the use of Immulon I plates (Dynatech Laborato­
ries) in place of the two types of plates already mentioned. The second 
involved increasing the concentration of the Hb in the coating buffer (25 
yg/ml) and the temperature at which coating was done (25°C). In order to 
cut down nonspecific binding of the monoclonal antibodies to the plates, 
immediately after the wells were coated with antigen, a blocking agent, 2% 
BSA in coating buffer, was incubated at 37°C for 1 hour in the wells. 
Increasing the incubation temperature from 25°C to 37°C, for all but the 
last step of the ELISA, was also included. 
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The most significant change was the addition of another antibody layer 
to the assay. In place of the R-xMGG-AP, rabbit anti-mouse y globulin 
(R-xMGG) (Sigma) at a 1:1500 dilution, was used. After a 2 hour incubation 
at 37°C, the excess R-xMGG was washed out and a 1:400 dilution of goat 
antl-rabbit-alkaline phosphatase conjugate (G-xBGG-AP) in PBS-20, was 
added. The incubation period was again 2 hours at 37°C. The addition of 
the substrate and subsequent incubation was not altered. The A^ QQ was 
again determined using the semi-automated microcuvette and Gilford 250 
spectrophotometer. 
When It was necessary to prepare R-xMGG-AP, a glutaraldehyde conjuga­
tion described by Voiler e£ , (1978) was used. Three hundred ]il of 
alkaline phosphatase (Sigma Type VII, Sigma) was centrlfuged at 1000 g for 
10 minutes at 4°C. The supernatant was discarded and 0.1 ml of purified 
R-xMGG (Cappel Laboratories, Westchester, PA) added. The mixture was 
dialyzed, overnight, against 4£ of PBS. The next morning, 10 yl of a 4.2% 
glutaraldehyde solution were added and the solution was incubated at room 
temperature for 2 hours. Enough PBS was then added to bring the volume to 
1 ml, the solution transferred to dialysis tubing and dialyzed, overnight, 
against 0.05 M Tris-HCl, pH 8.0, containing 100 yg of MgClg and 0.01% NaN^. 
The next day the volume was increased to 5 ml with the Tris-HCl buffer, and 
5% BSA (Sigma) was added as a stabilizer. 
Production of Monoclonal Antibodies 
Cell fusions were carried out using the procedure of Gefter et al., 
(1977), a modification of that used by K'ohler and Mllstein (1975). Mice 
were sacrificed by cervical dislocation 4 days following the last Injection 
63 
of antigen. Lymphocyte suspensions were prepared from their spleens by 
asceptlcally pressing the spleens through a sterile, 40-mesh, stainless 
steel screen. Cells were suspended in cold Dulbecco's modified Eagle's 
medium (GIBCO), supplemented with 2 mM glutamine (GIBCO), 1% antibiotic-
antimycotic (AA) (GIBCO), and 50 pg/ml garamycin (GRS)(Schering) (SF-DME). 
Exponentially proliferating NS-1 cells, or Sp2/0 cells, were washed 
once in SF-DME. These cells had been maintained in SF-DME supplemented 
with 15% fetal bovine serum (FBS) (Sterile Systems, Logan, UT or GIBCO), in 
a 37°C Incubator, with a humid 5% CO^ in air atmosphere (standard condi­
tions). The NS-1 cells are a nonsecreting, K-chain-synthesizing myeloma 
cell line. The Sp2/0 myeloma does not synthesize any heavy or light Ig 
chains. Lymphocytes and myeloma cells were mixed either at 5 lymphocytes 
per 1 myeloma cell, when NS-1 cells were used, or at equal numbers, when 
Sp2/0 cells were used. The cell mixture was centrifuged at 200 g for 8 
minutes. After removal of the supernatant, 1 ml of 45% polyethylene glycol 
1540 (Baker) previously filtered through a 0.22 ym Millipore filter, was 
added to the pellet slowly over a period of 45 seconds. The solution was 
Incubated for 45 additional seconds in a 37°C water bath, followed by the 
addition of 1 ml of SF-DME, during 1 minute, while gently shaking the tube. 
This was followed by another 10 ml of SF-DME added over 3 minutes. The 
cells were then centrifuged at 225 g for 8 minutes. After carefully 
removing the supernatant, cells were resuspended, using a wide-mouth 1 ml 
pipette, into either conditioned medium (CM) or conditioned selective 
medium (CHAT) (see below). 
Conditioned medium was obtained from the culture medium of the myeloma 
cells used. After filtering the medium through a 0.22 pm filter, it was 
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diluted with an equal volume of fresh DME. Using the 8-channel multi-
pipetter and pipette tips with the ends cut off, 200 jil of the cells were 
aliquoted at either 5.0 x 10^ cells/ml or 2.5 x 10^ cells/ml into each well 
of a 96-well, flat bottom, microtiter plate (Flow Laboratories, Inc., 
McLean, VA). If cells were initially plated in CM without HAT, the next 
day, 100 jjl of medium were removed from the wells and 100 yl of CHAT added. 
Cells were then fed every third day by removing 100 yl of old medium and 
adding 100 yl of fresh CHAT. Supematants were screened at days 14 and 21 
using the ELISA technique previously described. Cells from positive wells 
were transferred to 24-well culture plates (Costar) in 1.0 ml of fresh CHT 
medium (CHAT without aminopterin) and cultured until growth was confluent. 
2 They were then transferred to 25 cm tissue culture flasks containing 10 ml 
of CM. Cloning was done by diluting the cells to an average concentration 
of 2.5 cells/ml in CM, which had been supplemented with an additional 5% 
FBS (20% FBS final concentration), and 0.2 ml aliquots seeded into micro­
titer wells (96 wells/plate). Within 24 hours, wells were examined under 
phase and low power (60x) using a Wilde Inverted Phase Microscope, for 
single cells or obvious newly divided doublets. Then, 7 to 14 days later, 
clonal supematants were tested by the ELISA technique and positive clones 
propagated as above. Portions of exponentially growing clones were frozen 
in CM supplemented with an additional 5% FBS and 10% DMSO (Fisher), using a 
Union Carbide Biological Freezer (type BF-5) over liquid N^. Frozen cells 
were then kept in liquid until ready to be used. 
Ascites fluid was prepared by injecting 1 to 2 x 10^ hybridoma cells 
into a DBA/2 or BALB/c mouse that had previously been innoculated, at the 
time of fusion, with 0.5 ml tetramethyl pentadecane (Pristane, Aldrich 
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Chemical). Mice were observed 4-5 days later and daily thereafter. They 
were tapped successfully after appearance of ascites tumors. The isotypes 
of the monoclonal antibodies produced were established by Ouchterlony gel 
diffusion, or by the ELISA procedure, where subclass specific rabbit 
anti-TOouse-Ig (Miles Laboratories, Elkhart, IN) was used in place of the 
R-xMGG. 
35 S-methionine labeling of monoclonal antibodies 
Actively Ig-secreting hydridomas were grown to log phase by splitting 
the culture, 1 to 2, every 24 hours for 3 days. Cells were then collected 
in 15 ml centrifuge tubes and centrifuged at 200 g for 5 minutes. The 
supernatant was discarded and the cells washed once in 15 ml of either 
methionine-deficlent RPMI 1640 medium (GIBCO), supplemented with 15% FBS, 
1% AA and 0.5% GRS (RPMI 1640[-]), or methionine-deficlent HBlOl serum-free 
medium (HANA MEDIA, Inc., Santa Barbara, CA), supplemented with 1 mM sodium 
pyruvate, 2 mM glutamine, 1% HBlOl supplement, 1% AA and 0.5% GRS 
(HB101[-]). Cells were recentrifuged and resuspended to a concentration of 
1-2 X 10^ cells/ml in either RPMI 1640(-) or HBlOl(-) and 3 ml aliquoted to 
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a 25 cm tissue culture flask. S-labelled methionine (600-1400 Ci/raM 
specific activity) (Amersham, Elk Grove, IL) was added to each flask to a 
35 
concentration of 250 Ci/ml. Usually, the S-methlonlne, which was stored 
at -70°C in a Revco freezer, was thawed Immediately before use and 1 mCl 
suspended in 1 ml of the appropriate medium. Cells were incubated at 
standard conditions for 18 hours, after which the supernatant was harvested 
and centrifuged at 200 g for 8 minutes. The supernatant was carefully 
removed and transferred to clean 15 ml centrifuge tubes. 
66 
35 Incorporation of S-methionine was checked as follows: (a) 5 yl of 
sample were placed Into 1 ml of ice cold 10% trichloroacetic acid and 
incubated on ice for 10 minutes, (b) The sample was poured over 0.22 pm 
Millipore filter and allowed to completely dry. (c) The filter was placed 
into 5 ml of scintillation fluid, mixed and then counted using a Beckman LS 
1500 scintillation counter (Beckman Instruments). 
SDS-polyacryamide gel electrophoresis of monoclonal antibodies (Laemmli, 
1970) 
The use of sodium dodecyl sulphate (SDS) in electrophoresis causes the 
proteins in the system to become negatively charged with similar charge to 
weight ratios. This allows separation of the proteins based on size and 
shape and not on charge. 
Monoclonal antibodies were prepared for electrophoresis by mixing 
50 yl of the sample with 50 yl of sample buffer (2% SDS, 5% 2ME, 30% 
glycerol). They were then heated in a boiling water bath for 3 minutes. 
Gels were prepared in essentially the same way as those used in Hb 
electrophoresis, but with different buffers. The separating gel (7.5% T, 
2.67%C) was prepared as follows. 7.5 ml of acrylamide (30%), 6.0 ml of 
bisacrylamide (1%) 5.0 ml of separating buffer (3 M Tris-HCl, pH 8.8), 
0.2 ml SDS and 0.03 ml TEMED are mixed together and the final volume 
brought up to 30 ml with ddHgO. The solution was degassed and 0.3 ml of 
APS (1 mM) added to Initiate polymerization. The gel was then poured as 
before. 
The stacking gel (3%T, 2.67%C) consisted of 1.0 ml acrylamide (30%), 
0.8 ml bisacrylamide (1%), 1.25 ml stacking buffer (0.5 M Tris-H^PO^, pH 
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6.7), 0.1 ml SDS (10%), 0.01 ml TEMED and 6.3 ml ddH^O. After degassing, 
0.1 ml of 1 mM APS was added and the gel poured. 
After applying the samples, both the upper reservoir and lower reser­
voir were filled with electrode buffer (0.025 M Tris, 0.19 M glycine, 0.1% 
SDS, pH 8.2). Fifty yl of 0.1% bromphenol blue were added to the upper 
chamber as a tracking dye. Connections to the power supply were made such 
that the positive electrode, or anode, was in the lower chamber. Constant 
power of 3 watts was applied to the gel for 2h to 3 hours or until the 
tracking dye ran to within 1-2 cm of the bottom of the gel. Staining and 
destaining of the gels were carried out as previously described. 
Drying of slab gels 
After gels were destained, they were dried in one of two ways, depend­
ing on whether gel bond was used as a gel support. 
If no gel support was used during electrophoresis, gels were dried 
onto Whatman 1 filter paper using a BioRad gel drier. Two sheets of filter 
paper (200 x 300 mm) were placed, back to back, onto the suction grid of 
the gel drier and flooded with ddH^O. Air bubbles were removed from 
beneath the paper by gently pushing them off to the side with a gloved 
finger. The gel was then placed on the top sheet and air bubbles were 
removed. The gel was covered by a mylar sheet (BioRad) and the rubber 
gasket on the gel dryer carefully placed over the filter paper-gel-mylar 
sheet combination. The gel dryer was hooked to an aspirator and vacuum 
applied. The drier was turned on for 2 hours at medium heat. After 
drying, the gel was bound to the top layer of filter paper and was stored 
in a notebook, if not radioactive. If the gel was radioactive, it was 
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covered with Saran Wrap and stored at -70°C in X-ray exposure holders until 
used in autoradiography. 
If gel bond was used as a backing for the gel, drying was simply a 
matter of air-drying the gel. Curling of the gel bond was prevented by 
placing large books over the edges. Within 2 days the gel had dried to a 
thin sheet permanently bonded to the gel bond. Gels were again stored in a 
notebook to prevent curling, if non-radioactive, or covered with Saran Wrap 
and stored at -70°C in holders, if radioactive. 
Autoradiography of monoclonal antibodies 
35 S-labeled gels, previously dried on filter paper or gel bond, were 
placed, gel next to emulsion, on XAR-5 X-ray film (Kodak). All work with 
the X-ray film was done under a 6B-X-ray safelight (Kodak) in a darkroom. 
The gel and film were then placed into X-ray exposure holders. Exposures 
of 18-20 hours were sufficient to produce clearly defined bands. 
Films were developed, at room temperature, for 2 minutes in Kodak 
GBX-developer, 1 minute in the stop solution and 10 minutes in Kodak GBX 
fixer. They were then washed in cold ddHgO for 60 minutes, dipped into a 
0.1% solution of Photo-flo solution (Kodak) and allowed to air-dry. 
Concentration of protein solutions 
Two methods were used to concentrate protein solutions, ultrafiltra­
tion and ammonium sulphate precipitation. The method chosen depended on 
the protein. To concentrate Hb, ultrafiltration was always used. Wlien 
monoclonal antibodies were concentrated, (NH^)2S0^ precipitation was used. 
This had the added advantage of partially purifying the antibody from the 
rest of the supernatant proteins, i.e. FBS, albumin, etc. 
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The use of an Amlcon ultra filtration apparatus to concentrate pro­
teins was very straightforward. A PM 10 filter (Amicon Corporation, 
Lexington, MA) was washed for 1 hour In ddH^O and placed in the appropriate 
Amicon apparatus, the choice dependent on the volume of the original 
sample. After placing the sample in the filter chamber, a head pressure of 
30 psl of Ng was applied and the sample monitored until the required volume 
was reached. 
To concentrate Igs, (NH^)2S0^ was usually used. To a constantly 
stirred 10 ml volume of supernatant, 7.5 ml of saturated (NH^)2S0^ 
(S(NH^)2S0^) was added dropwise. The solution was stirred for 2 hours 
after which it was centrifuged at 1500 g in a TJ-6 centrifuge. The super­
natant was discarded and the pellet resuspended to its original volume in 
PBS. An additional 7.5 ml of S(NH^)2S0^ was again added dropwise and the 
mixture stirred for 1 hour. After centrifuging, the supernatant was then 
discarded and the pellet resuspended in 1 ml of PBS and extensively 
dialyzed against PBS. 
Monoclonal antibody Ig Isotype determination 
The isotypes of the various monoclonal antibodies were determined 
either by Ouchterlony double diffusion analysis (Ouchterlony, 1949; Garvey 
et al., 1977) or by ELISA. Double diffusion plates (Miles Laboratories) 
were prepared using 1% agarose, 0.1% sodium azlde in either PBS or BBS 
(borate buffered saline). Fifteen jil of "monoclonal supernatant," concen­
trated at least 10 times by either (NH^)2S0^ precipitation or using an 
Amicon ultrafiltration apparatus as previously described, were placed in 
one of six wells surrounding a center well filled with 15 1 Isotype-
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specific antisera. Six monoclonal antibodies could be screened against 3 
isotype-speclfic antisera per plate. Precipitation lines could be observed 
within 24 hours at room temperature. 
To more clearly distinguish the precipitation lines, the gel was first 
removed from the plates and then washed in 10 changes of PBS for 48 hours. 
The gel was then placed on a 10 cm x 10 cm glass plate previously coated 
with 0.1% solution of agarose. Four pieces of Whatman 1 filter were placed 
over the gel and any air bubbles squeezed out. Five paper towels were then 
placed over the filter paper and a 1 kg weight was placed on top of the 
towels. An hour later, the filter paper and towels were carefully removed 
and the gel placed into a 75®C oven until dry. It was stained by Immersion 
into a 40% methanol, 7% acetic acid, 1% Coomassie Brillant Blue R250 
solution for 3 minutes. The gel was immediately destalned by rinsing it in 
3 changes of destainlng solution, (40% methanol, 7% acetic acid), and then 
allowed to air-dry. 
When the isotype of the monoclonal antibody was determined using 
ELISA, the procedure previously described was followed. The only change 
was to substitute class-specific R-xMGG (Miles Laboratories, Elkhart, IN) 
in place of the polyspecific R-xMGG. 
Statistical Analysis 
A Duncan's Multiple Range Test was used to determine significant 
differences among the strains of mice tested. A student's t-test was used 
to determine significant differences between HbA and HbS inoculated mice. 
When comparing the reactivities of the monoclonal antibodies, the mean of 
the A,values of the first four serum dilutions was used as the mean of 
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the graph. These values had background values subtracted before calcula­
tion of the mean and were tested for significant differences again by the 
Duncan's Multipe Range Test (Steel and Torrie, 1980). 
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RESULTS 
Hemoglobin Purification 
A summary of the Hbs used in these experiments is found in Table 8. 
The variants of HbA^  and HbS were chosen on the basis of 4 criteria, 1) 
that the amino acid substitution occur on the external surface of the 
molecule, 2) that there would be a change in the overall charge of the 
molecule, 3) that they would separate from HbA^ or HbS by ion exchange 
chromatography and during electrophoresis, and 4) that they were available. 
The initial work in this study focused on two Hbs, HbAj^ and HbS. 
These were purified from the hemolysate of sickle-cell trait blood using 
the modified procedure of Huisman and Dozy (1965). A typical elution 
profile is shown in Figure 7. The initial peak to come off the column 
contained HbA^ , a minor Hb found at low concentrations in most adults. HbS 
was the next Hb to be eluted and was clearly separated from HbAj, which 
followed. The remaining peak, which eluted after HbA^, was probably HbF. 
Since both HbA^ and HbF were available commercially at a reasonable price, 
it was decided to discard the small amounts obtained from purifying HbA^ 
and HbS. When HbC was purified, it eluted off the column directly follow­
ing HbAg. 
When variants other than HbS and HbC were purified, a 5-step pH and 
ionic strength gradient was used to elute the desired Hb. The sequence of 
buffers used depended on the relative mobility of the Hb to that of HbA^  or 
HbS and can be found in Table 10. The elution profiles of 3 Hbs, Hbl, Hb 
0-Indonesia and Hb J-Baltimore, are shown in Figure 8 a-c. 
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Table 8. Summary of hemoglobins used to screen monoclonal antibodies 
(Lehmann and Kynoch, 1976) 
Hemoglobin 
HbA 
HbS 
HbS+^  
HbA 
HbF 
HbC 
HbE 
Hbl 
HbC-Harlem 
Hb D-Iran 
Hb D-LA 
Hb G-Georgia 
Hb G-Philadelphia 
Hb N-Seattle 
Hb N-Baltlmore 
Hb 0-Indonesla 
Hb Q-Indla 
Hb Arya 
Hb Beograd 
Hb Hasharon 
Hb Hopkins II 
Hb Korle-Bu 
Hb Montgomery 
Hb Russ 
Hb Zurich 
Position 
Chain Residue # 
0 6 
B 6 
ô 
Y 
0 6 
0 26 
a 16 
0 6 
73 
0 22 
0  121  
a 95 
a 68 
0 61  
0  121  
a  116  
a 64 
a 47 
0 121 
a  47 
a 112 
0 73 
a 48 
a 51 
0 63 
Substitution 
HbA^  Variant 
glu val 
glu val 
0 6 
0 Y 
glu lys 
glu lys 
lys glu 
glu val 
asp asn 
glu glu 
glu glu 
pro leu 
asn lys 
lys glu 
lys glu 
glu lys 
asp his 
asp asn 
glu val 
asp his 
his asp 
asp asn 
leu arg 
glu arg 
his arg 
^ Fe+++ as opposed to Fe++. 
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Figure 7. Purification of HbA, and HbS from HbAS blood (solid line) 
(Fractions were collected in 10 ml volumes. pH gradient is 
shown by the dashed line.) 
Figure 8. Purification of (a) Hbl; (b) Hb J-Baltimore, and (c) Hb 0-Indonesia (Arrows with 
letters indicate the buffer used and its time of application) 
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When Hbl was purified, the initial buffer was 75 ml of followed by 
60 ml of D and then E to elute the Hbl from the column. When O-Indonesia 
was purified, the Hb was eluted behind HbA^ using 75 ml of buffer B, 48 ml 
of buffer C and the rest of the Hb eluted with buffer E. Hb J-Baltimore 
was to elute after HbA  ^and HbA, so a sequence similar to that for Hbl was 
followed. All of the Hbs separated in this manner, eluted in narrow bands 
and were usually monitored visually. The use of the stepwise gradient 
allowed for much greater resolution than the procedure followed to purify 
Hbs Aj, S and C. Without this approach, it was very difficult to obtain 
clear separation and thereby pure Hb. Figure 9 shows the electrophoretic 
heterogeneity of some of the hemolysates before purification and Figure 10 
the corresponding pure Hb. 
Purification of the a and g chains of HbA^ and HbS 
Although the purification of o and g chains from Hb has been an 
established procedure for 20 years, yields have remained low and the 
resultant subunlts were unstable. The modifications used in this protocol 
have allowed for more stable subunlts and resulted in higher yields than 
those achieved using the classical purification (Bucci and Fronticelli, 
1965). 
A significant loss of material occurred in the overnight incubation of 
Hb with PCMB. A large amount of precipitate formed and after centrifuglng, 
up to 30% of the original starting material was lost. This problem was 
present whether or not EDTA was present. It was also noticed that, after 
centrlfugatlon, precipitate continued to form. The addition of EDTA seemed 
to slow down this process. The removal of PCMB by desalting the solutions. 
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Figure 9. EXectrophoretic separation of some variant Hbs' hemoXysates 
(Lane 1, HbA; Lane 2, a chain; Lane 3, 3 chain; Lane 4, Hbl; 
Lane 5, Hb Zurich; Lane 6, HbE; Lane 7, Hb 0-Indonesia; Lane 8, 
Hb J-Baltimore; Lane 9, Hb C-HarXem; Lane 10, Hb N-BaXtimore; 
Lane 11, Hb Russ; Lane 12, Hb Hopkins 2; Lane 13, Hb Q-India; 
Lane 14, Hb Montgomery; Lane 15, HbS; Lane 16, HbA; Lane 17, Hb 
Hasharon; Lane 18, Hb Arya; Lane 19, Hb N-Seattle; and Lane 20, 
Hb D-LA.) 
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12 3 4 5 6 7 8 9 101112 131415 
Figure 10. Electrophoresis of some purified Hb variants (Lane 1, HbAS; 
Lane 2, N-Baltimore; Lane 3, N-Seattle; Lane 4, Hbl; Lane 5, 
Hopkins II; Lane 6, Hasharon; Lane 7, D-LA; Lane 8, 
J-Baltimore; Lane 9, Q-India; Lane 10, C-Harlem; Lane 11, 
D-Iran; Lane 12, O-Indonesia; Lane 13, G-Philadelphia; Lane 14, 
Korle-Bu; Lane 15, Arya. Twenty micrograms of each Hb were 
added to each well) 
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using a G-25 column, rather than by dialysis, also decreased subsequent 
precipitation. 
To separate the a and g chains from each other, the classical proce­
dure called for a CM-cellulose column and an increasing pH gradient. This 
allowed the g chains to elute first and then the a chains. A major problem 
with this was the precipitation of a large amount of the a chains and 
subsequent instability of the a chains once eluted. Geracl et al., (1969) 
suggested splitting the a/3 chain mixture and using 2 separate columns, 
CM-cellulose and DEAE-cellulose to elute one or the other chain. Under the 
conditions described, the a-chalns would elute in the void volume of the 
DEAE-cellulose and the 3-chalns in the void volume of the CM-cellulose. 
The obvious drawback to this method was the loss of 50% of the available 
subunits, since the remaining chains were not eluted from the columns. The 
use of a DEAE-Sephacel column, however, as well as EDTA, allowed the use of 
a single column, and gave a and g chains that were very stable in solution 
(Figure 11 a-b). 
Another area where a major loss of material occurred was In the 
regeneration of the SH groups. The procedures described by Bucci and 
Fronticelll (1965) and Geraci et al., (1969) resulted in losses of 
material, due to precipitation on the column, of up to 80% of the starting 
material. When the modification of Valdes and Ackers (1977) was used, 
however, this loss was almost negligible. The method was effective in 
regenerating the SH chains and left little precipitate on the column. 
Values for the A 250/270 ratio were approximately 0.78 for the a chains and 
0.82 for the g chains, consistent with published data (Winterhalter and 
Colosimo, 1971). 
Figure 11. Elution of the a- and 3-chains of (a) HbA^ and (b) HbS (The a-chains were eluted 
first, unsplit Hb second and the g-chains eluted last. Initial buffers for both 
columns were 0.01 M phosphate, 0.001 M EDTA, pH 8.0. The first arrow indicates a 
change to 0.02 M phosphate, 0.001 M EDTA buffer. The second indicates the switch 
to 0.01 M phosphate, 0.001 M EDTA buffer) 
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Determination of Antl-Hb Serum Antibody in Inbred Mice 
Enzyme-linked immunoabsorbant assay (ELISA) 
To optimize the conditions for the ELISA, experiments were undertaken 
to determine the most efficient concentration of antigen with which to coat 
the wells and the best concentration of enzyme-antibody conjugate to use. 
Figure 12 shows that 1.0 yg/ml of Hb was sufficient to saturate the wells 
with antigen. When concentrations of Hb greater than 1.0 yg/ml were used, 
no significant change was detected in the A^^^ value. At concentrations 
lower than 1.0 yg/ml, the A^^^ dropped off rapidly. On the basis of this 
experiment, a working concentration of 5.0 yg/ml was chosen. 
To determine the correct dilution of RxMGG-AP, a constant amount of 
HbA^ was coated on the wells and a 1:100 dilution of DBA/2 or normal DBA/2 
serum anti-HbA^  serum used as the source of MGG. RxMGG-AP, serially 
diluted within the plate, was then added and the assay completed. Results 
would vary from preparation to preparation, so it was important to titer 
out each lot of enzyme-antibody conjugate. Figure 13 shows a typical 
titration curve. Normally a 1:400 or 1:500 dilution was considered the 
best dilution to use since it gave A^ ^^  values greater than 2.0 while 
keeping the values of NMS below 0.15. 
The effect of antigen dose on the antibody response 
Three groups of six DBA/2 mice were injected, with either 1 yg, 20 yg 
or 100 yg of HbAj in their hind foot pads and boosted, ip, with identical 
dosages of antigen, in PBS, 21 days later. The results demonstrated that a 
dose of 20 yg/mouse would give a response higher than either of the other 
dosages (Figure 14). Therefore, 20 yg was chosen as the optimal dose for 
subsequent immunizations of the other strains. 
SBie£^ . 
Figure 12. Titration of Hb concentration necessary to coat the ELISA plates (BALB.B anti-HbA, 
antiserum (x-x) or BALB.B normal serum (0-0) were used at a 1:100 dilution) 
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Figure 13. Determination of the optimal SxMGG-AP concentration to use in a double antibody 
indirect ELISA (DBA/2 antiserum, diluted 1:500 (x-x), 1:1000 (0—0), 1:2000 (a—a), 
1:4000 (A-A), 1:8000 (x....x) and 1:16000 (•-.-•), was tested against increasing 
dilutions of RxMGG-AP. 1:500 was chosen as the optimal dilution since an ABS,of 1.0 
was still seen at the highest dilution of DBA/2 antiserum) 
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Figure 14. Effect of antigen dose on specific anti-HbA^  antibody 
concentration 
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Affinity chromatography of antl-Hb standard 
To quantitate the amount of anti-Hb antibody present In each of the 
serum samples, a standard amount of antl-Hb antibody was Included in each 
ELISA plate. To determine the concentration of the standard, affinity 
columns, containing either HbA^  or HbS, were used. 
Figure 15a shows the elutlon profile of 0.3 ml of antl-HbAj antibody 
and Figure 15b shows the elutlon of 0.3 ml of anti-HbS antibody. The 
protein concentration of the two eluted fractions, anti-HbAj and antl-HbS, 
were found to be similar (Table 9). This suggested that the valine 
substitution in HbS had little or no effect on the amount of antibody 
produced and that little or no antibody was produced only against this 
substitution. To further investigate this, anti-HbS standard anti-serum 
was passed through an HbA^-affinlty column. If any large amount of 
antibody were "anti-val," a decrease In the amount of protein eluted from 
the column would be seen. This was, however, not the case (Table 9). 
After elutlon of the anti-HbS antibody, its activity was measured and 
found to be less than that of untreated antibody. There were three possi­
ble explanations for this; 1) not all the antl-Hb antibody was absorbed to 
the column and some was left in the initial fractions or; 2) not all the 
anti-Hb antibody was eluted from the column, or 3) the elutlon of the 
antibody by using a low pH buffer affected its activity. An ELISA profile 
of the Initial, eluted and original fractions (Figure 16), showed that all 
the anti-Hb antibody was bound to the column, since all the activity had 
been removed from the initial fraction. The possibility that some of the 
specific antibody had been left on the column was also discounted when 
anti-HbS antiserum, treated with the eluting buffer, 1 M CH^COOH, for the 
Figure 15. Purification of standard (A) antx-HbA^  and (B) anti-HbS polyclonal antibodies 
(Samples were collected in 3 ml fractions. Eluting buffer, 1 M CH COOH, was 
added after fraction 6 (A) or 8 (B) to elute the specific antibody) 
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Table 9. Quantitation of specific antl-HbA, or antl-HbS antibody 
Eluted 
Antigen antibody Mean eluted 
used for Exp. concn. antibody concn. 
Type of column Immunization No. (pg/ml) Cpg/ml) 
HbA,-Sepharose HbA, 1 80 
o
 
+1 o
 
2 60 
HbS-Sepharose HbS 1 52 61 ± 9 
2 70 
HbAj^ -Sepharose HbS 1 70 — — —  
Figure 16. Activity of affinity-purified anti-HbA- antibody (ELISA profile of the pre-column 
sample (x-x), the passed fraction (a-a;, and the eluted fraction (•—o). Decrease in 
the activity of the pre-column sample after treatment with the eluting buffer (0—0) is 
also shown) 
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same period of time as the eluted antibody, gave a similar loss of activity 
(Figure 16). 
Although this loss of activity was unfortunate, it was not a major 
problem. The goal of this experiment had been to determine the amount of 
specific antibody, and this was accomplished. There was no need for 
purified antibody as a standard. In fact, using affinity purified antibody 
would have had more minuses than pluses. It was noted, for example, that 
affinity purified anti-Hb antibody had a tendency to aggregate and 
precipitate out of solution. Additionally, the protein concentration of 
the unknown serum samples would have been 100 to 1000 times as great as the 
purified antibody and may have contributed nonspecific serum effects to the 
assay. Using anti-Hb whole serum would compensate for these effects. 
Quantitation of serum antibody levels 
The determination of anti-Hb antibody was initially done for 5 con-
genlc strains of mice. At least 6 mice from each strain were Inoculated 
with each Hb; each received 20 yg of either HbA^ or HbS on day 1 and an 
additional 20 yg, 21 days later. The assays were performed as described 
previously and representative graphs are shown in Figures 17 a-c. Some 
strains were very consistent in their response (Figure 17a), while others 
gave a range of values differing by an order of magnitude (Figure 17c). 
Distinct differences were found in the magnitude of the responses between 
strains, but little or no difference within the strains to HbA^^ or HbS 
(Table 10). Since these strains differed only in the MHC region, control 
of this re- sponse can, at least partially, be attributed to the H-2 
complex. This was confirmed by results obtained from mice congenic on the 
Figure 17. The anti-HbS response of three strains of mice ("The 
serum of three strains of mice; (A) BALB.K, (B) BALB.B 
and (C) BALB/C were tested for the presence of anti-HbS 
antibody by ELISA. Each assay included both an antl-HbAj 
standard serum (x-x) and an anti-HbS standard serum 
(0-0). Five mice were tested for the BALB.K strain, five 
for the BALB.B strain and six for the BALB/C strain. 
Lines were fitted by a computer using a logarithmic 
regression) 
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Table 10. Antibody response of C57BL/10 congenic mice to HbAj^  and HbS^  
HbAj HbS 
Strain 
H-2 
haplotype 
No. mice 
tested 
Anti-HbA 
concn. 
(mg/ml) 
1 
(SEM) 
No. mice 
tested 
Anti-HbS 
concn. 
(mg/ml) (SEM) 
C57BL/10Sn b 9 0.98*'* (0.19) 13 1.15*'* (0.12) 
BIO.A a 6 1.59* (0.41) 6 1.7]* (0.37) 
BIO.BR k 14 0.55* (0.16) 14 0.78* (0.12) 
B10.D2 d 7 1.76* (0.18) 14 2.68* (0.45) 
BIO.S s 8 0.54* (0.12) 10 0.36* (0.03) 
 ^w,x: values with different letters are significantly different at 
P<0.05. 
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BALB/c background (Table 11). Those mice with the k (BIO.BR, BALB.K) 
haplotype were found to be low responders, whereas mice with the d or b 
haplotype were high responders. The results obtained from the BALB.B 
(H-2b) mice also suggest the influence of non-H-2 genes in this response, 
since they were significantly higher responders than the BIO (H-2b) mice. 
The role of non-H-2 genes was investigated further by the use of 
noncongenic inbred mice. When comparing mice with the same H-2 haplotype 
but with different backgrounds (Table 12), a clear difference was observed 
between the SJL mice and the BlO.S mice, again suggesting that non-H-2 
genes are involved in regulating this response. 
Although the magnitude of the response to the intact molecule was not 
noticeably affected by the valine substitution, the level of antibody 
directed against determinants Involving, or close to, the 6th position of 
the 3 chain, might have been. Table 13 is a summary of the data obtained 
when serum samples from five strains of mice, previously inoculated with 
either HbS or HbA^ , were tested for antibody specific for the N-terminal 
octapeptldes of HbA^  and HbS. The standard used as an Internal control was 
a monoclonal antibody, D2-A9, which was found to react with both the 3^ 1 
and 3® peptides. It was an IgM-producing clone; therefore, the results 
were presented as percent of control and not in yg/ml. For the most part, 
the results follow the pattern of response to the intact molecules. The 
g 
one exception, BIO anti-3 , was found to give a lower response than to both 
intact molecules, as well as to the 3^  peptide. Due to complications which 
arose soon after this experiment was finished, this observation was not 
repeatable. This will be dealt with in more detail in later discussion. 
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Table 11. Antibody response of BALB/c congenic mice to HbA^  and HbS^  
HbAj HbS 
Anti-HbA^  Anti-HbS 
H-2 No. mice concn. No. mice concn. 
Strain haplotype tested (mg/ml) (SEM) tested (mg/ml) (SEM) 
BALB/c d 6 1.81* (0.53) 6 1.46* (0.29) 
BALB.B b 5 1.16*'^  (0.31) 5 1.37*'^  (0.36) 
BALB.K k 6 
00 o
 
o
 
d
 5 0.26? (0.01) 
 ^x,y,z; values with different letters are significantly different at 
P<0.05. 
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Table 12. Antibody response of inbred mice to HbAj and HbS^  
HbAj HbS 
Anti-HbAj^  Anti-HbS 
H-2 No. mice concn. No. mice concn. 
Strain haplotype tested (mg/ml) (SEM) tested (mg/ml) (SEM) 
C57BL/10Sn b 9 0 98W,x (0.19) 13 1 .15*'* (0. 12) 
BIO.A a 6 1 .59* (0.41) 6 1 .71* (0. 37) 
BIO.BR k 14 0 .55* (0.16) 14 0 .78* (0. 12) 
B10.D2 d 7 1 .76* (0.18) 14 2 .68* (0. 45) 
BIO.S s 8 0 .54* (0.12) 10 0 .36* (0. 03) 
BALB/c d 6 1 .81* (0.53) 6 1 .46* (0. 29) 
BALB.B b 5 1 .16*'Z (0.31) 5 1 .37*'^  (0. 36) 
BALB.K k 6 0 .18? (0.08) 5 0 .26? (0. 01) 
CBA k ND^  ND 5 0 .67* (0. 08) 
DBA/1 q ND ND 6 0 .71* (0. 22) 
DBA/2 d 14 1 .81* (0.28) 6 2 .66^  (0. 42) 
SJL s 6 2 .96= (0.82) ND ND 
 ^w,x,y,z; Values with different letters are significantly different 
at P<0.05. 
 ^ND = not done. 
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Table 13. Antibody resj 
octapeptides 
]ogse of inbred mice to the g^ l and g S 
g^ l Peptide g^  Peptide 
Strain Haplotype 
No. mice 
tested % Control (SEM) 
No. mice 
tested % Control(SEM) 
DBA/2 d 8 51(17)*'*'? 4 65(12)*'*'? 
BIO b 8 74(15)* 7 35(3)? 
B10.D2 d 7 93(16)* 8 108(27)* 
BIO.BR k 8 32(8)*'? 8 44(4)*'? 
BIO.S s 8 33(3)*'? 7 39(1)*'? 
3 A Anti-HbAj^  sgras were tested against the g 1 peptide and antl-HbS 
sera against the g -peptide. Thg control was a monoclonal, D 2-A9, found 
to react with both the g 1 and g peptides. 
 ^w,x,y: values with different letters are significantly different 
P<0.05. 
103 
Production and Characterization of Monoclonal Antibodies 
Over a period of 2 years, 10 separate fusions were attempted, seven of 
which gave clones which secreted Ig capable of reacting with Hb. A total 
of 16 antibody-producing clones were produced, ten of which remained viable 
and capable of producing antibody throughout the course of this 
investigation. The remaining six either died, were contaminated or simply 
stopped producing antibody. 
Table 14 presents a summary of all 16 clones. The first four anti­
bodies were produced from fusions involving NS-1 myeloma cells, the rest 
used Sp2/0 cells. All were IgMs with the exception of two, 13 and 9. 
Mab 13 was the lone IgG producing clone. Unfortunately, soon after 
the initial screening, done with protein A-alkallne phosphatase, the clone 
began to lose its ability to produce antibody. Attempts to concentrate 
enough antibody to give a precipitin line in Ouchterlony analysis were 
unsuccessful and isotype determination by ELISA gave results that were 
inconclusive. Successive clonings of this clone soon showed that It had 
stopped producing antibody that would react with Hb. 
The second non-IgM antibody produced, #9, was also produced in low 
amounts. After concentrating the antibody, by (NH^ )2S0^  precipitation, its 
isotype was determined, by Ouchterlony analysis, to be IgA. 
Autoradiography (Figure 18) clearly showed differences between 9 and the 
rest of the antibodies, with a heavy chain at 65K and light chain at 25K. 
Of all the monoclonal antibodies produced, the one which was most 
Interesting, #1, was lost due to a bad lot of fetal bovine serum. This 
antibody was Interesting since It seemed to bind the peptides homologous to 
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Table 14. Summary of monoclonal antibodies produced 
Name No. 
Myeloma 
cell 
Spleen 
cell 
Fusion 
Isotype Antigen 
Survival 
viable 
Antibody 
production 
D2A9 1 NS-1 BALB/c 1 IgM HbA^  No -
D2G10 lb NS-1 BALB/c 1 IgM HbA^  Yes Yes 
E1E6 2 NS-1 DBA/2 2 IgM HbS Yes Yes 
G7D6 3 NS-1 DBA/2 3 IgM HbS Yes Yes 
DABI 4 Sp2/0 DBA/2 4 IgM HbS Yes Yes 
1G8 9 Sp2/0 B10.D2 5 IgA HbS Yes Yes 
8C10 5 Sp2/0 B10.D2 6 IgM HbS Yes Yes 
6C10 11 Sp2/0 B10.D2 6 IgM HbS Yes No 
20A1 12 Sp2/0 B10.D2 7 IgM HbS Yes No 
20B2 14 Sp2/0 B10.D2 7 IgM HbS Yes No 
119A 7 Sp2/0 B10.D2 7 IgM HbS Yes Yes 
4C1 6 Sp2/0 B10.D2 7 IgM HbS Yes Yes 
4C4 15 Sp2/0 B10.D2 7 IgM HbS Yes No 
I5A6 13 Sp2/0 B10.D2 7 IgG?* HbS Yes No 
8D4 10 Sp2/0 B10.D2 7 IgM HbS Yes Yes 
16G7 16 Sp2/0 B10.D2 7 IgM HbS Yes No 
19F9 8 Sp2/0 B10.D2 7 IgM HbS Yes Yes 
 ^15A6 was determined to be an IgG done by binding of protein 
A-alkaline phosphatase. Soon after this, the clone began to lose its 
ability to produce antibody. 
Figure 18. Autoradiography of 14 monoclonal antibodies (Fourteen 
Nabs were labelled with S methionine as described. The 
Igs were purified using saturated ammonium sulfate and 
approximately 50,000 cpn's added to each lane. Lane 1, 
Sp2/0 supernatant; Lane 2, Mab 14; Lane 3, Nab 13; Lane 4, 
Nab 10; Lane 5, Nab 16; Lane 6, Nab 6; Lanes 7 and 8, high 
and low molecular weight standards; Lane 9, Mab 14; Lane 
10, Nab 8; Lane 11, Nab 11; Lane 12, Nab 9; Lane 13, Nab 
4, Lane 14, Mab 7; Lane 15, Nab lb; Lane 16, Sp2/0 
supernatant; Lanes 17 and 18, standards; Lane 19, Mab 12; 
Lane 20, Mab 2; Lane 21, Mab 3) 
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the octapeptlde at the N-termlnal end of the g-chains of HbA^  and HbS. It 
was during this period of investigation that the clone was lost. Cells 
from the freezer were found to be viable, only to die within days of being 
thawed. The original #1 clone was not recovered. In fact, 7 of the 8 
clones in the freezer died. The eighth clone, a subclone of the original, 
was finally revived using a new fetal bovine serum, HyClone. 
It was an unfortunate mistake to not test each lot of fetal bovine 
serum before using it as a growth supplement. When Sp2/0 cells were grown 
in the bad lot of FBS and in the new lot obtained from Sterile Systems, a 
dramatic difference was seen in viability and doubling time (Figure 19). 
Enhancement of the screening assay for monoclonal antibodies 
The ELISA assay used for the quantitation of serum antibody was 
sufficient when dealing with a heterologous population of antibody at high 
concentration. When screening monoclonal antibodies, however, the need to 
enhance the sensitivity of the ELISA assay soon became apparent. In the 
first 4 fusions, only 4 monoclonal antibodies were obtained and all were 
IgM. Since IgM was a pentamer, it had the ability to bind more RxMGG-AP 
conjugates and select preferentially for IgM producing hybridomas. 
To enhance the sensitivity of the assay, the RxMGG-AP was replaced 
with RxMGG alone and the AP coupled to GxRGG. The resultant increase was 
substantial, approximately 30 fold (Figure 20). 
To optimize the conditions for this new ELISA, two further experiments 
were done. The amount of RxMGG was varied and found to saturate the amount 
of antibody bound to the plate at dilutions up to 1:3200 (Figure 21). 
Next, the amount of goat-xRGG-AP was varied. Dilutions of 1:400 - 1:800 
Figure 19. Effect of different fetal bovine sera on Sp2/0 myeloma cells (2 X 10 Sp2/0 cells 
were inoculated into 10 ml of medium contaning either 10% GIBCO, 10% HyClone or 15% 
HyClone FBS. Cell numbers were determined every 24 hours for 5 days) 
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Figure 20. The effect of a third antibody in enhancing the sensitivity of ELISA (The titer of Mab 
1 was determined using a two antibody (o—Q) or three antibody (x-x) ELISÂ. Sp 2/0 
supernatant was also tested in both systems, (0-0) three antibody, (A-A) two 
antibodies. RxMGG, SxMGG-AP and GxRGG-AP were used at 1:500 dilutions) 
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Figure 21. The titration of varied concentrations of RxMGG on the sensitivity of the three-
antibody ELISÂ G)BA/2 anti-HbS antiserum was diluted 1:500 and allowed to bind 
to the Hb coated mlcrotiter wells. Increasing dilutions of RxMGG were added to each 
well, followed by increasing dilutions of GxRGG-AP, (x-x) 1:400, (0-0) 1:800, 1:1600 
(•_•) and 1:3200 (A-A)) 
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were sufficient to give adequate values (Figure 22). 
Since this assay was clearly superior to the previous one, it was 
decided to use it for the rest of the investigation. 
Use of blocking agents to decrease nonspecific binding to the ELISA plates 
Initially, when parameters for the ELISA were being determined, a 
negative control, which had no antigen in the wells, was included. The 
results of this control were negative for each antiserum tested. When the 
first three monoclonals were titered out, they also had negative controls 
which were negative. At this time, Dynatech Laboratories, the company 
which supplied the substrate plates being used, discontinued the plate in 
favor of a new, cheaper and more "reliable" ELISA plate, Immulon II. The 
only supplier of the old substrate plates was in Germany and the cost 
became prohibitive, so a change was made to the Immulon II plates. 
The initial results were indeed encouraging (Figure 23). The increase 
in absorbance was dramatic and there was no Increase in the amount of 
nonspecific binding of the antiserum to the wells. This was consistent 
with the earlier plates and so the negative control, which had been nega­
tive for all the monoclonal antibodies tested, was not included when 
screening began using the octapeptides as antigens. When antibody 1 
reacted with both the peptides and the intact molecules, it was assumed the 
antibody was against the peptides. The other two monoclonals, 2 and 3, 
only reacted against the intact molecules (Figures 24 a-c). 
It was at this point that the clone producing antibody 1 was lost and 
a subclone established that was thought to be producing the same antibody. 
It was soon apparent that antibody IB reacted with the peptides as well as 
Figure 22. The titration of varied concentrations of GxRGG-AP on the sensitivity of the three-
antibody ELISÂ (DBA/2 anti-HbS antiserum was used at a dilution of 1:500. 
Increasing dilutions of BxMGG were added to each well, (x-x) 1:400; (0-0) 1:800; and 
1:1600, followed by increasing dilutions of GxRGG-AP) 
1 1 1 1 1 1 1 1 
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Figure 23. Comparison of Inmulon II substrate plates with EIA substrate plates (Mab la was used 
at a dilution of 1:20. Immulon II (0-0) showed a significant increase in absorbance 
when compared to the EIA plates (x-x)) 
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Figure 24. ELISA titration curve for (a) Mab la, (b) Nab 2 and (c) Mab 3, when tested against 
HbAj^ , B peptide, HbS and B peptide. 
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antibody 1 did; however, the Inability of antibody IB to distinguish 
between the 4 peptides was worrisome. To determine If antibody IB bound to 
the peptides or to the unbound sites on the polystyrene plate, a set of 
wells with no antigen bound was Included In a normal ELISA procedure. The 
results. Figure 25, demonstrated that the antibody was binding, at best, to 
both the plate and the antigen and at worst, binding only to the plate. 
In order to block any sites on the wells that might bind antibody, two 
proteins, BSA and gelatin, were coated on the wells following the coating 
of the antigen. Unfortunately, this did nothing to alleviate the problem 
(Figure 25). When IB was tested using the original plates, the background 
was within reason (Figure 26). It was decided to discontinue the use of 
Immulon II plates. 
Another Dynatech plate, Immulon I, was tested after this and found not 
to bind IB nonspeclflcally when coated with 1% gelatin directly following 
the coating of antigen (Figure 27). Therefore, Immulon I plates were used 
for the rest of the experiments. 
Binding of antibody by HbS and met HbS 
A problem in the use of Hb as an antigen lies in Its transformation 
from COHbS to met HbS on prolonged storage. Precautions were taken to 
prevent this; the Hb was stored under CO, at an alkaline pH and at 4°C or 
less. Some samples, those obtained commercially and purified from other 
laboratories, contained significant amounts of met Hb, (10-15%). The 
effect of met Hb on the binding of the anti-Hb antibodies was investigated 
and found to be insignificant when polyclonal antiserum was used as a 
source of antibody (Figure 28). When monoclonal antibodies were used, only 
Figure 25. Nonspecific binding of Mab lb Lu Immulon II plates (Mab lb (1:20) was allowed to bind 
with decreasing amounts of Kb. Blocking agents were either 1% BSA (Q^ ), 1% gelatin 
(0-0) or carbonate buffer alone (x-x)) 
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Figure 26. The effect of varied blocking agents on the nonspecific binding of Nab lb to the 
original ELISA plates (Nab lb (1:20 dilution) was allowed to bind with decreasing 
amounts of Hb blocking agents which were either 1% BSA (•-•), 1% gelatin (0-0) or 
carbonate buffer alone (x-x)) 
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Figure 27. Binding of Mab lb to Inmulon I plates coated with HbÂ^  (x-x) or carbonate buffer (0-0) 
alone 
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one was affected by the change to met Hb. 
Effect of unbound HbS on the final reactivity of monoclonal antibodies 
toward bound Hb. 
Competition experiments were carried out using all ten of the mono­
clonal antibodies. The results were interesting since it was not possible 
to block the reactivity of the antibody for Hb with unbound Hb. Figure 29 
points out the problem. When polyclonal antiserum was used, in this case 
BALB.B x-HbS, small amounts of unbound Hb were all that were needed to 
effectively compete for the antibody. On the other hand, the monoclonal 
antibody tested, 2, was unaffected in its affinity for bound Hb, by even 
the addition of 1 mg/ml of Hb. This was also the case with the rest of the 
monoclonal antibodies. One major difference between the polyclonal anti­
serum and the monoclonals tested, was that the polyclonal antiserum was 
mainly IgG and the monoclonals, IgM. 
Although these results may imply that the antibody is not against Hb, 
the rest of the evidence suggests otherwise. Later discussion will provide 
some possible explanations. 
Screening of monoclonal antibodies against octapeptides 
The 10 monoclonal antibodies were screened against the 3®, S^ , and 
3™^  peptides. The results. Table 15, indicated that of the 10 monoclonal 
antibodies, none reacted with any of the peptides, suggesting no antibody 
was directed against this area of the molecule. Antibody 1 did react 
against all the peptides, as previously discussed, but those results are 
now questionable. 
Figure 28. The effect of met-Hb on the binding of BALB.B anti-HbA^  antibodies 
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Figure 29. Effect of unbound HbS on the final reactivity of monoclonal antibodies toward bound 
HbS (Competition experiments were carried out using either BALB.B anti-HbS polyclonal 
serum (1:20, x-x) (1:200, 0-0) or Mab 2 supernatant (1:2-, (1:20,^ )^) 
ug HbS/Well 
Table 15. Summary of monoclonal reactivity against the 4 octapeptides 
Antibody HbA^  HbS A-pep S-pep MA-pep MS-pep 
IB 2.96 (0.04) 2.92 (0.01) 0.34 (0.02) 0.36 (0.07) 0.41 (0.07) 0.41 (0.03) 
2 2.96 (0.03) 2.94 (0.02) 0.18 (0.01) 0.11 (0.05) 0.06 (0.03) 0.05 (0.01) 
3 2.94 (0.03) 2.91 (0.01) 0.20 (0.01) 0.18 (0.05) 0.19 (0.03) 0.20 (0.05) 
4 0.73 (0.04) 0.53 (0.03) 0.03 (0.01) 0.10 (0.07) 0.11 (0.10) 0.04 (0.02) 
5 2.70 (0.16) 2.78 (0.04) 0.12 (0.06) 0.05 (0.02) 0.03 (0.01) 0.04 (0.02) 
6 1.66 (0.01) 1.50 (0.04) 0.08 (0.04) 0.09 (0.03) 0.07 (0.03) 0.05 (0.05) 
7 2.96 (0.06) 2.92 (0.03) 0.14 (0.00) 0.28 (0.10) 0.19 (0.03) 0.16 (0.02) 
8 0.49 (0.02) 0.46 (0.04) 0.08 (0.05) 0.10 (0.03) 0.11 (0.09) 0.09 (0.04) 
9 0.40 (0.11) 0.29 (0.01) 0.11 (0.03) 0.05 (0.02) 0.04 (0.10) 0.05 (0.03) 
10 1.31 (0.18) 1.29 (0.26) 0.17 (0.05) 0.12 (0.02) 0.10 (0.08) 0.07 (0.01) 
 ^Values are A^ QQ of a 1:4 dilution of monoclonal supernatant. 
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Titration of Hbs with different electrophoretlc mobility and charge 
To determine the effect that the Hbs charge had on its ability to 
bind to the polystyrene plates, 5Hbs; HbC, HbS, HbA, Hbl and HbJ were bound 
at decreasing concentratlon(s) to mlcrotlter wells. BÂLB.B antl-HbA 
antiserum was then used at a concentration of 1:100 to provide a source of 
antibody. The results. Figure 30, Indicated that the different Hbs all 
saturated the binding sites of the well at about the same concentration. 
This meant that differences found In the reactivity of the monoclonal 
antibodies tested, would be due to changes In the Hbs antigenic structure, 
and not In the amount of Hb bound to the plate. 
Reactivity of polyclonal antlsera against variant Hbs and Hb subunlts 
Antl-HbS antlsera from 4 strains of mice were tested against the panel 
of variant Hbs and Hb subunlts. The results are shown In Table 16. All 
the antlsera reacted equally with the majority of the Hbs. All four 
samples showed a significant decrease In their reactivity to the Beta chain 
of Hbs, and two showed a loss of reactivity to Hb D-LA. One showed a 
decrease in Its reactivity to Hbl. The implications of these results will 
be discussed later. 
Reactivity of monoclonal antibodies to variant Hbs 
All ten monoclonal antibodies were tested against 23 of the 27 Hbs or 
subunlts available. Four of the 10 were also tested against an additional 
4 Hbs, of limited quantity (Table 17). 
Of the 10 antibodies tested, 80% reacted significantly less with the g 
chain of Hb (Table 18), than with the Intact molecule or with the a subunit. 
All showed variability in their reactivities toward the variants. 
135 
some more than others. Of the 83 differences noted, 16% were significantly 
higher than the reactivity toward the original antigen, Hbs, the rest were 
lower. An in-depth discussion of these results will be found later. 
Figure 30. Titration of Hbs with different electrophoretic mobility and charge (Varied amounts of 
either HbS (x), HbA (0), HbC (o), Hbl (^ ) or Hb J-Baltimore (+) were coated on Innnulon 
I plates. BALB.B anti-HbS antiserum was used at a 1:100 dilution) 
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Table 16. Reactivity of polyclonal antlsera against variant Hbs 
Strain Plate Hemoglobin Graph Mean (SD) % of Control 
C57BL/10Sn 
C57BL/I0Sn 
C57BL/10Sn 
C57BL/10Sn 
HbS 0 .676 (0. ,165) 100 .00 
HbS+ 0 .776 (0. ,125) 114 .68 
Alpha 0 .731 (0. ,153) 108 .09 
Beta 0 .424 (0. 176) 62 .66 
HbA 0 .770 (0. 170) 113 .80 
HbAg 0, .690 (0. 156) 102 .00 
HbS 0, .743 (0. 166) 100 .00 
HbE 0, .760 (0. 142) 102 .26 
Hbl 0, .688 (0. 195) 92 .64, 
D-LA 0, .568 (0. 190) 76 .38^  
0-Indonesia 0, .720 (0. 148) 96 .86 
Q-India 0, .652 (0. 203) 87 .74 
J-Baltimore 0, .700 (0. 185) 94 .23 
Zurich 0, .633 (0. 173) 85 .13 
HbS 0, .645 (0. 154) 100, .00 
Montgomery 0. ,723 (0. 108) 112, .12 
Arya 0. 613 (0. 172) 95, .02 
G-Philadelphia 0. ,672 (0. 100) 104, .31 
D-Iran 0. ,656 (0. 166) 101. ,69 
Hopkins II 0. 614 (0. 133) 95. ,19 
N-Seattle 0. ,587 (0. 216) 91, ,10 
HbS 0. 727 (0. 175) 100. ,00 
Russ 0. 769 (0. 142) 105. ,74 
N-Baltimore 0. 752 (0. 163) 103. 52 
Korle-Bu 0. 770 (0. 142) 105. ,92 
C-Harlem 0. 807 (0. 171) 111. ,09 
Hasharon 0. 733 (0. 176) 100. 91 
Beograd 0. 805 (0. 164) 110. 76 
G-Georgla 0. 803 (0. 144) 110. 47 
Results are grouped as Individual ELISÂ plates and mean values 
compared within each plate, but not between plates. 
Significantly lower than HbS at P< 0.05. 
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Table 16. Continued 
Strain Plate Hemoglobin Graph Mean (SD) % of Control 
B10.D2 1 HbS 0.663 (0.123) 100.00 
HbS+ 0.736 (0.099) 110.99 
Alpha 0.727 (0.092) 109.54, 
Beta 0.477 (0.191) 71.93 
HbA 0.735 (0.099) 110.79 
HbA, 0.678 (0.138) 102.19 
HbC'^  0.765 (0.082) 115.27 
HbF 0.655 (0.130) 98.73 
B10.D2 2 HbS 0.637 (0.113) 100.00 
HbE 0.648 (0.076) 101.70 
Hbl 0.567 (0.097) 88.93 
D-La 0.561 (0.113) 88.07 
0-Indonesia 0.572 (0.075) 89.81 
Q-India 0.589 (0.111) 92.40 
J-Baltimore 0.618 (0.115) 97.08 
Zurich 0.592 (0.084) 92.87 
B10.D2 3 HbS 0.672 (0.106) 100.00 
Montgomery 0.712 (0.100) 105.83 
Arya 0.630 (0.114) 93.62 
G-Philadelphia 0.644 (0.114) 94.82 
D-Iran 0.662 (0.097) 98.51 
Hopkins II 0.619 (0.099) 92.12 
N-Seattle 0.590 (0.146) 87.70 
B10.D2 4 HbS 0.550 (0.083) 100.00 
Russ 0.708 (0.084) 128.79 
N-Baltimore 0.657 (0.081) 119.56 
Korle Bu 0.685 (0.093) 124.71 
C-Harlem 0.693 (0.073) 126.04 
HaSharon 0.681 (0.093) 123.89 
Beograd 0.714 (0.118) 129.92 
G-Georgia 0.734 (0.096) 133.65 
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Table 16. Continued 
Strain Plate Hemoglobin Graph Mean (SD) % of Control 
BIO.A 
BIO.A 
BIO.A 
BIO.A 
HbS 0 .637 (0. ,204) 100 .00 
HbS+ 0 .708 (0. ,159) 111 .20 
Alpha 0 .645 (0. ,190) 101 .30 
Beta 0 .449 (0. 177) 70 .49^  
HbA 0 .702 (0. 178) 110 .24 
HbA, 0 .570 (0. 144) 89 .49 
HbC^  0 .742 (0. 165) 116 .58 
HbF 0 .543 (0. 155) 85 .36 
HbS 0 .679 (0. 160) 100 .00 
HbE 0, .677 (0. 160) 99. 81 
Hbl 0, .584 (0. 197) 86 .10 
D-LA 0, .515 (0. 168) 75, .88^  
O-Indonesla 0, .161 (0. 168) 90, .78 
Q-Indla 0, .577 (0. 201) 84, .97 
J-Baltlmore 0. 641 (0. 176) 94, .44 
Zurich 0, .595 (0. 160) 87, .64 
HbS 0. ,699 (0. 189) 100, .00 
Montgomery 0. 752 (0. 162) 107, .54 
Arya 0. ,667 (0. 219) 95. 34 
G-Philadelphia 0. ,659 (0. 182) 94. ,24 
D-Iran 0. ,695 (0. 217) 99. ,43 
Hopkins II 0. ,659 (0. 190) 94. ,22 
N-Seattle 0. 672 (0. 230) 96. ,15 
HbS 0. 663 (0. 193) 100. ,00 
Russ 0. 696 (0. 197) 104. ,88 
N-Baltimore 0. 651 (0. 183) 98. ,13 
Korle-Bu 0. 664 (0. 196) 100. ,17 
C-Harlem 0. 712 (0. 169) 107. 30 
Hasharon 0. 634 (0. 193) 95. 58 
Beograd 0. 700 (0. 195) 105. 58 
G-Georgia 0. 661 (0. 212) 99. 70 
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Table 16. Continued 
Strain Plate Hemoglobin Graph Mean (SD) % of Control 
BAL6.B 
BALB.B 
BALB.B 
BALB.B 
HbS 1 .016 (0.660) 100 .00 
HbS+ 1 .153 (0.648) 113 .44 
HbA 1 .003 (0.710) 98 .68 
HbA_ 1 .197 (0.740) 117 .83 
HbC"^  1 .178 (0.626) 115 .97 
HbE 0 .990 (0.665) 97 .42 
HbF 0 .889 (0.719) 87 .50, 
Hbl 0 .523 (0.402) 51 .45' 
HbS 0 .912 (0.662) 100 .00 
Alpha 1, .124 (0.702) 123. 20, 
Beta 0, .185 (0.160) 20, ,30' 
HbS 1, .013 (0.728) 100, .00 
G-Philadelphia 1, .011 (0.728) 99, .81 
C-Harlem 1, .134 (0.711) 111, .97 
Korle Bu 0. 853 (0.676) 84, .23 
D-Iran 1, .019 (0.695) 100, .56 
Arya 1. 001 (0.613) 98, ,80 
Hasharon 1. 291 (0.771) 127. 45 
Montgomery 1. 105 (0.652) 109. ,10 
HbS 1. ,138 (0.670) 100. ,00 
Zurich 1. 006 (0.595) 88. ,35 
G-Georgla 1. 177 (0.779) 103. ,44 
Russ 1. 036 (0.809) 91. 06 
D-LA 1. 088 (0.664) 94. 60 
J-Baltimore 1. 016 (0.706) 89. 24 
N-Baltlmore 1. 053 (0.691) 92. 51 
Beograd 0. 959 (0.622) 84. 27 
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Table 17. Reactivity of monoclonal antibodies to variant Hbs^  
Monoclonal 
Antibody Plate Hemoglobin Graph Mean (SD) % of Control 
1 1 HbS 0.225 (0.192) 100.00 
HbS+ 0.177 (0.191) 78.54 
HbA 0.183 (0.170) 80.98 
HbA- 0.086 (0.220) 38.27 
HbC 0.283 (0.236) 125.50 
HbE 0.251 (0.259) 111.49. 
HbF 0.005 (0.067) 2.31% 
Hbl 0.044 (0.060) 19.69^  
1 2 HbS 0.288 (0.242) 100.00 
Alpha 0.264 (0.196) 91.66. 
Beta 0.070 (0.091) 24.30® 
Mouse 0.170 (0.126) 59.00 
HbS 0, ,333 (0.241) 100, .00 
G-Philadelphia 0, .148 (0.188) 44, .35 
C-Harlem 0. ,423 (0.472) 127, .22 
Korle-Bu 0. ,146 (0.171) 43, .90 
D-Iran 0. ,187 (0.192) 56, .22, 
Arya 0. ,074 (0.094) 22, 36° 
Hasharon 0. ,405 (0.377) 121. ,66 
Montgomery 0. 194 (0.092) 58. ,23 
HbS 0, .412 (0.287) 100, .00 
Zurich 0, ,177 (0.238) 42, .98° 
G-Georgia 0, .342 (0.218) 82. ,97 
Russ 0. ,361 (0.384) 87, ,68 
D-LA 0. ,272 (0.201) 66. ,08 
J-Baltimore 0. ,296 (0.240) 71. 94 
N-Baltlmore 0. ,174 (0.179) 42. ,25^  
Beograd 0. ,446 (0.397) 108. ,36 
® Results are grouped as Individual ELISA plates and mean values 
compared within each plate, but not between plates. 
^ Significantly lower than HbS at P<0.05. 
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Table 17. Continued 
Monoclonal 
Antibody Plate Hemoglobin Graph Mean (SD) % of Control 
2 • 1 HbS 0.773 (0.417) 100.00 
HbS+ 0.505 (0.320) 65.33, 
Alpha 0.429 (0.246) 55.48^  
Beta 0.521 (0.295) 67.37 
HbA 0.704 (0.388) 91.05 
HbA- 0.726 (0.399) 93.89 
HbC 1.076 (0.473) 139.16, 
HbF 0.362 (0.256) 46.78" 
2 2 HbS 0.780 (0.410) 100.00 
HbE 0.786 (0.442) 100.79 
Hbl 0.496 (0.264) 63.63, 
D-LA 0.253 (0.190) 32.47" 
D-Indonesia 0.747 (0.385) 94.69 
Q-India 0.515 (0.286) 66.07 
J-Baltlmore 0.699 (0.315) 89.63 
Zurich 0.353 (0.290) 45.30 
2 3 HbS 0.877 (0.523) 100.00 
Montgomery 0.687 (0.380) 78.31 
Arya 0.017 (0.013) 1.96^  
G-Phlladelphla 0.789 (0.381) 89.95 
D-Iran 0.923 (0.474) 105.26 
Hopkins II 0.447 (0.289) 50.99^  
N-Seattle 0.488 (0.351) 55.60 
Mouse 0.517 (0.382) 59.00 
2 4 HbS 0.698 (0.390) 100.00 
Russ 0.601 (0.308) 86.04. 
N-Baltlmore 0.398 (0.254) 56.92^  
Korle-Bu 0.638 (0.323) 91.36 
C-Harlem 0.849 (0.392) 121.57 
Hasharon 0.540 (0.366) 77.29 
Beograd 0.677 (0.360) 96.92 
G-Georgia 0.701 (0.344) 100.32 
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Table 17. Continued 
Monoclonal 
Antibody Plate Hemoglobin Graph Mean (SD) % of Control 
HbS 0 .709 (0.442) 100 .00 
HbS+ 0 .707 (0.377) 99 .66 
Alpha 0 .770 (0.443) 108 
.56b 
Beta 0 .158 (0.075) 22 .28° 
HbA 0 .683 (0.405) 96 .35 
HbA- 0 .569 (0.316) 80 .23 
HbC 0 .776 (0.414) 109 .42 
HbF 0 .646 (0.339) 91 .10 
HbS 0 .782 (0.421) 100 .00 
HbE 0 .768 (0.415) 98 .12 
Hbl 0 .605 (0.365) 77 .31 
D-LA 0 .509 (0.317) 65 .06 
0-Indonesia 0 .689 (0.357) 88 .06 
Q-India 0 .577 (0.336) 73 .74 
J-Baltimore 0 .706 (0.368) 90 .19% 
Zurich 0 .393 (0.326) 50 .23 
HbS 0 .803 (0.444) 100 .00 
Montgomery 0 .814 (0.427) 101 .38 
Arya 0 .083 (0.062) 10 .40 
G-Philadelphla 0 .762 (0.391) 94 .92 
D-Iran 0 .811 (0.438) 100 .96 
Hopkins II 0 .676 (0.364) 84 .16 
N-Seattle 0 .556 (0.374) 69 .31, 
Mouse 0 .090 (0.072) 11 .2r 
HbS 0 .628 (0.361) 100 .00 
Russ 0 .663 (0.387) 105 .52 
N-Baltlmore 0 .567 (0.315) 90 .26 
Korle-Bu 0 .597 (0.325) 94 .97 
C-Harlem 0 .814 (0.367) 129 .64 
Hasharon 0 .740 (0.401) 117 .82 
Beograd 1 .014 (0.353) 161 .42= 
G-Georgia 1 371 (0.645) 218 .33 
Significantly higher than HbS at P<0.05. 
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Table 17. Continued 
Monoclonal 
Antibody Plate Hemoglobin Graph Mean (SD) % of Control 
HbS 0 .309 (0.178) 100 .00 
HbS+ 0 .215 (0.118) 69 .53 
HbA 0 .174 (0.113) 56 .22 
HbA„ 0 ,136 (0.078) 43 .98 
HbC 0 .449 (0.275) 145 .37^  
HbE 0 .300 (0.067) 97 22, 
HbF 0 .140 (0.087) 45 
•"b 
Hbl 0 .086 (0.086) 27 .98^  
HbS 0 .081 (0.176) 100 .00 
Alpha 0 .248 (0.181) 306 .29% 
Beta -0 019 (0.012) -23 .18 
HbS 0 197 (0.077) 100 .00 
G-Philadelphla 0 131 (0.091) 66 •63 
C-Harlem 0. 498 (0.046) 253 .02^  
Korle-Bu 0 099 (0.044) 50 
D-Iran 0 109 (0.136) 55 36^  
Arya 0. 031 (0.067) 15 54^  
Hasharon 0. 275 (0.127) 139 72^  
Beograd 0. 089 (0.037) 45 35^  
HbS 0. 251 (0.123) 100 00 
Zurich 0. 270 (0.085) 107. 62. 
G-Georgla 0. 125 (0.140) 49 76° 
J-Baltlmore 0. 145 (0.130) 57 74. 
D-LA 0. 094 (0.085) 37 48° 
Arya 0. 164 (0.079) 65 5 k 
N-Baltlmore 0. 126 (0.142) 50 28° 
Montgomery 0. 256 (0.186) 102. 07 
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Table 17. Continued 
Monoclonal 
Antibody Plate Hemoglobin Graph Mean (SD) % of Control 
HbS 0 .184 (0. 156) 100 .00 
HbS+ 0 .071 (0. 090) 38 .70^  
HbA 0 .105 (0. 103) 56 .90 
HbA, -0 .019 CO. 042) -10 .27^  
HbC 0 .173 (0. 177) 94 .24, 
HbE 0 .083 (0. 074) 45 .16^  
HbF 0, .094 (0. 085) 50 .92 
Hbl 0, .007 (0. 041) 3 .91^  
HbS 0, ,212 (0. 198) 100, .00 
Alpha 0, .230 (0. 177) 108, 29 
Beta -0, .001 (0. 023) -0, .61° 
HbS 0. ,105 (0. 128) 100, ,00 
G-Philadelphia 0. ,177 (0. 136) 168, 38 
C-Harlem 0. ,320 (0. 169) 304, ,95^  
Korle-Bu 0. ,123 (0. 083) 117, ,43 
D-Iran 0. ,080 (0. 145) 75. ,90 
Arya 0. ,054 (0. 089) 51. 33 
HaSharon 0. ,213 (0. 186) 202. ,48^  
Beograd 0. ,084 (0. 067) 79. ,62 
HbS 0. 168 (0. 121) 100. 00 
Zurich 0. 104 (0. 106) 62. ,33 
G-Georgia 0. 091 (0. 107) 54. 
"b J-Baltimore 0. 070 (0. 084) 42. 03° 
D-LA 0. 048 (0. 075) 28. 78^  
Russ 0. 092 (0. 112) 54. 63 
N-Baltimore 0. 101 (0. 105) 60. 06 
Montgomery 0. 150 (0. 124) 89. 61 
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Table 17. Continued 
Monoclonal 
Antibody Plate Hemoglobin Graph Mean (SD) % of Control 
HbS 1 .092 (0.530) 100 .00 
HbS+ 0, .975 (0.441) 89 .26 
HbA 0, .872 (0.497) 79 .85, 
HbA, 0, .448 (0.233) 41 .01^  
HbC 0, .888 (0.598) 81 .31 
HbE 0, .727 (0.306) 66 .57 
HbF 1, .130 (0.526) 103 .46 
Hbl 0, .470 (0.246) 43 .05^  
HbS 0. ,867 (0.514) 100 .00 
Alpha 0, ,796 (0.466) 91, .79. 
Beta 0. ,227 (0.097) 26, .20* 
HbS 0. ,743 (0.418) 100, .00 
G-Phlladelphia 0. ,903 (0.333) 121 ,  56 
C-Harlem 0. 897 (0.400) 120 .  73 
Korle-Bu 0. 783 (0.315) 105. ,41 
D-Iran 0. 723 (0.414) 94, .30 
Arya 0. 503 (0.210) 67. ,68 
Hasharon 0. 914 (0.458) 122. 94 
Beograd 0. 657 (0.298) 88. ,43 
HbS 1. 115 (0.466) 100. ,00 
Zurich 1. 103 (0.414) 98. ,95 
G-Georgla 1. 268 (0.468) 113. ,71 
J-Baltimore 1. 239 (0.398) 111. ,07 
D-LA 1. 518 (0.361) 136. 12 
Russ 0. 687 (0.312) 61. 62° 
N-Baltimore 0. 969 (0.479) 86. 86 
Montgomery 1. 125 (0.424) 100. 88 
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Table 17. Continued 
Monoclonal 
Antibody Plate Hemoglobin Graph Mean (SD) % of Control 
HbS 0.462 (0.312) 100.00 
HbS+ 0.314 (0.369) 68.08 
HbA 0.372 (0.320) 80.58, 
HbA_ 0.118 (0.095) 25.49° 
HbC 0.219 (0.198) 47.42 
HbE 0.086 (0.130) 18.64 
HbF 0.208 (0.177) 45.13 
Hbl 0.414 (0.325) 89.69 
HbS 0.299 (0.277) 100.00, 
Alpha 0.200 (0.154) 66.69° 
Beta 0.333 (0.259) 111.29, 
Mouse 0.175 (0.173) 58.50 
HbS 0.248 (0.248) 100.00 
G-Phlladelphla 0.247 (0.230) 99.60 
D-Harlem 0.382 (0.340) 154.40 
Korle-Bu 0.196 (0.106) 79.28 
D-Iran 0.232 (0.214) 93.82 
Arya 0.108 (0.135) 84.09 
HaSharon 0.214 (0.291) 86.31 
Montgomery 0.198 (0.130) 79.85 
HbS 0.160 (0.220) 100.00 
Zurich 0.269 (0.236) 168.34 
G-Georgla 0.313 (0.254) 195.81 
Russ 0.367 (0.508) 229.66 
D-LA 0.385 (0.208) 240.68 
J-Baltimore 0.354 (0.227) 221.65 
N-Baltlmore 0.258 (0.202) 161.20 
Beograd 0.137 (0.173) 85.79 
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Table 17. Continued 
Monoclonal 
Antibody Plate 
8 1 
Hemoglobin Graph Mean (SD) % of Control 
HbS 0.948 (0.361) 100.00 
HbS+ 1.051 (0.409) 110.85 
Alpha 1.285 (0.519) 135.50, 
Beta 0.566 (0.177) 59.66" 
HbA 1.009 (0.271) 106.42 
HbA, 1.028 (0.263) 108.48 
HbC 1.390 (0.431) 146.65^  
HbF 0.789 (0.270) 83.23 
HbS 0.964 (0.433) 100.00 
HbE 0.902 (0.335) 93.58 
Hbl 0.744 (0.209) 77.17 
D-LA 1.109 (0.394) 115.05 
0-Indonesla 1.100 (0.333) 114.13 
Q-Indla 0.972 (0.291) 100.86 
J-Baltlmore 1.151 (0.176) 119.49, 
Zurich 0.594 (0.365) 61.60 
HbS 0.954 (0.256) 100.00 
Russ 0.853 (0.367) 89.49 
N-Baltlmore 0.714 (0.241) 74.85 
Korle-Bu 0.673 (0.294) 70.60 
C-Harlem 0.791 (0.281) 82.95 
Hasharon 0.641 (0.345) 67.25° 
Beograd 0.601 (0.241) 63.03 
G-Georgla 0.687 (0.228) 72.03 
HbS 0.722 (0.398) 100.00 
Montgomery 0.681 (0.314) 94.25 
Arya 0.422 (0.337) 58.40° 
G-Phlladelphia 0.782 (0.311) 108.29 
D-Iran 0.637 (0.303) 88.20 
Hopkins II 0.893 (0.320) 123.66 
N-Seattle 0.545 (0.212) 75.44 
Mouse 0.530 (0.206) 73.41 
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Table 17. Continued 
Monoclonal 
Antibody Plate Hemoglobin Graph Mean (SD) % of Control 
HbS 0 .582 (0.413) 100 .00 
HbS+ 0 .683 (0.443) 117 .41 
Alpha 0 .735 (0.453) 126 .36 
Beta 0 .235 (0.101) 40 .38° 
HbA 0 .425 (0.272) 73 .01 
HbA 0 .482 (0.256) 82 .75 
HbC 0 .640 (0.372) 109 .95 
HbF 0 .461 (0.231) 79 .12 
HbS 0 .499 (0.311) 100 .00 
HbE 0 .604 (0.315) 121 .05 
Hbl 0 .456 (0.248) 91 .46^  
D-LA 0 .758 (0.355) 151 .96^  
0-Indonesia 0 .623 (0.297) 124 .88 
Q-Indla 0 .576 (0.221) 115 .46 
J-Baltimore 0 .546 (0.235) 109 .52 
Zurich 0 .550 (0.272) 110 .29 
HbS 0 .496 (0.300) 100 .00 
Montgomery 0 .461 (0.262) 93 .04 
Arya 0 .507 (0.309) 102 .18 
G-Philadelphia 0 .602 (0.358) 121 .50 
D-Iran 0 .453 (0.309) 91 .37 
Hopkins II 0 .591 (0.318) 119 .14 
N-Seattle 0 .356 (0.230) 71 .84 
HbS 0 .436 (0.301) 100 .00 
Russ 0 .474 (0.226) 108 .76 
N-Baltimore 0 .338 (0.176) 77 .44^  
Korle-Bu 0 .457 (0.232) 104 .82 
C-Harlem 0 .589 (0.373) 134 .97 
Hasharon 0 .490 (0.327) 112 .36 
Beograd 0 .398 (0.186) 91 .24 
G-Georgia 0 .486 (0.235) 111 .51 
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Table 17. Continued 
Monoclonal 
Antibody Plate Hemoglobin Graph Mean (SD) % of Control 
10 1 HbS 0. 250 (0.278) 100 .00 
HbS+ 0. 190 (0.282) 76 .09 
HbA 0 125 (0.159) 49 .78 
HbA 0 086 (0.133) 34 .51 
HbC 0. 499 (0.333) 199 .64^  
HbE 0. 294 (0.263) 117 .35 
HbF 0. 107 (0.104) 42 .82 
Hbl 0. 043 (0.028) 17 .23^  
10 2 HbS 0. 514 (0.369) 100 .00 
Alpha 0. 481 (0.317) 93 .62 
Beta 0. 025 (0.032) 4 .90^  
Mouse 0. 240 (0.210) 47 .00 
10 3 HbS 0. 545 (0.337) 100 00 
G-Philadelphia 0. 332 (0.286) 60 .94 
C-Harlem 0. 993 (0.533) 182 18^  
Korle-Bu 0. 295 (0.208) 54 Ik 
D-Iran 0. 255 (0.190) 46 75^  
Arya 0. 238 (0.134) 43 76° 
Hasharon 0. 582 (0.413) 106 86 
Montgomery 0. 209 (0.214) 38 45° 
10 4 HbS 0. 416 (0.357) 100 00 
Zurich 0. 354 (0.284) 84 99 
G-Georgia 0. 225 (0.185) 54 06 
Russ 0. 331 (0.335) 79 37b 
D-LA 0. 136 (0.175) 32 
"b 
J-Baltimore 0. 117 (0.091) 28. 
"'b 
M-Baltimore 0. 062 (0.088) 14. 96 
Beograd 0. 190 (0.146) 45. 73 
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Table 18. Summary of monoclonal antibody reactivity against variant Hbs 
Posit. Amino 
on Acid Monoclonal Antibody 
Hemoglobin Helix Molec. SubSt. 1 2 3 4 5 6 7 8 9 10 
HbS+ Fe+3 * * ft ft L ft ft ft ft ft 
Alpha chain - a - * L ft ft ft ft I, ft ft ft 
Beta chain - B - L * L L L L ft L L L 
HbA - 6 - A * ft L L L L ft ft L 
HbF - Y - L L ft L L ft L ft ft ft 
Hbl A14 al6 lys+glu L A ft I, T, L ft ft ft L 
Arya CD5 ot47 asp+asn I L L L ft L ft L ft T, 
Hasharon CDS «47 asp+his * * ft ft H ft ft L ft ft 
Montgomery CD6 «48 leu+arg * * ft ft ft ft ft ft ft L 
Russ CD9 aSl glu+arg A ft ft ft ft L ft ft ft ft 
G-Phil. E17 a68 asn+lys * ft ft ft ft ft ft ft ft ft 
G-Georgia G2 «95 pro+leu * ft H L ft ft ft ft ft ft 
HbA A3 86 val+glu * ft ft ft ft ft ft ft ft ft 
HbC A3 36 gliH-lys * ft ft ft ft ft L H ft H 
C-Harlem A3 86 lug+val 
* ft ft H H ft ft ft ft H 
E17 873 asp+asn 
J-Baltimore A13 816 gly+asp * ft ft ft L ft ft ft ft L 
D-Iran B4 822 glu+gln * ft ft L ft ft ft ft ft L 
HbE B8 826 glu+lys * ft ft ft * ft L L ft L 
Zurich E7 863 hie+arg L L I, ft ft ft ft L ft ft 
Korle-Bu E17 873 asp+arn * ft ft L ft ft ft ft ft ft 
N-Baltimore FG2 895 lys+glu L L ft L ft ft ft ft L L 
D-LA GH4 8121 glu+gln * L ft L L H H ft H T, 
Beograd GH4 8121 glu+val * ft H ft ft ft ft L ft ft 
Q-India E13 «64 asp-vhis * ft ft ND ND ND ND ft ft ND 
Hopkins II G19 «112 his+asp ND L ft ND ND ND ND ft ft ND 
0-Indonesia GH4 «116 glu+lys ND ft ft ND ND ND ÎJD ft ft ND 
N-Seattle E5 861 lys+glu ND L ft ND ND ND ND ft ft ND 
Hb Mouse L ft L ND ND ND L ft ND T. 
(B10.D2) 
* = Not significantly different from HbS at P<0.05. 
L = Significantly lower than HbS at P<P.05. 
H = Significantly higher than HbS at P<0.05. 
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DISCUSSION 
Murine Immune Response to Human Hbs 
The main thrust of this project has been to study the immune response 
of Inbred mice to human adult Hbs. This characterization had two main 
goals; 1) to determine the role the MHC plays in controlling this response, 
and 2) to partially define the antigenic determinants on the Kb molecule. 
The first goal has been accomplished using a series of mice differing 
only in their H-2 complex (congenic strains). These mice show clear 
differences in their levels of Hb-specific antibody. Table 12 (page 101), 
thereby indicating at least partial involvement of gene(s) residing in the 
H-2 complex. The reciprocal comparison, using mice of the same H-2 haplo-
type but different background genes, indicates the presence of geneCs) 
residing outside the MHC being involved as well. (Table 12, page 101.) 
For example, the SJL and BIO.S mouse strains have the same H-2 haplotype 
but different backgrounds, yet their anti-Hb humoral responses differ by an 
order of magnitude. Table 12. Comparison of the BALB.B strains (H-2^ ) 
response with that of the C57BL/10Sn strains (H-2^ ), further indicates the 
presence of a non-H-2 gene effect. 
It is interesting to note that the non-H-2 genes enhance the serum 
antibody response. It also appears that the mode of action of these two 
effects are different. In one case, a nonresponder haplotype, H-2^ , 
becomes a responder. In the other case, a responder haplotype, H-2^ , 
become an even higher responder. If the nonresponslveness of the BIO.S 
strain is due to a suppressor allele, as suggested by Krco e^  al., (1981a), 
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then the non H-2 gene found in the SJL background would be a contra-
suppressor. On the other hand, the enhancement of the H-2^ response might 
be a gene complementation effect. 
The precise location of the gene(s) within the H-2 complex was not 
determined since access to the numerous mouse strains needed was limited to 
only a few. At least one gene was found, however, to map to the D end of 
the H-2 complex. This was based on the responses elicited by the B10.D2 
(H-2^ ), BIO.BR (H-2^ ) and BIO.A (H-2^ ) mouse strains. A clear difference 
was evident between the B10.D2 and BIO.BR strains (Tables 10 and 12). The 
d k H-2 mice were highly responsive whereas the H-2 mice were low responders. 
The BIO.A strain's haplotype, H-2* (K^ , Ag^, A^^, Eg^ , l'^ ) is 
a result of recombination between haplotypes d and k (Klein et. , 1983). 
The recombination occurred to the right of the gene coding for the E 
chain and to the left of the S region. Since the BIO.A mice were high re­
sponders, as were the B10.D2 mice, at least one gene must then be found to 
the right of the I region. Since there has never been a report of the S 
region contributing to the genetic control of the immune response and its 
primary function is to code for serum proteins (Klein , 1982), it is 
more than likely that this gene(s) is located in the D or L region. 
Although the D region has seldom been shown to be involved in the control 
of the humoral response, Berzofsky et al., (1982) has shown the response to 
the related protein, myoglobin (Mb), to be partially controlled in a 
similar fashion. Krco et , (1981 a,b) have also demonstrated that the T 
cell proliferative response to human Hb is controlled by the DL region, as 
well as by genes found in the lA region. It is also noteworthy to consider 
the possibility that this gene might lie even further to the right, perhaps 
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in the Qa-2 or Tla regions. The actual location of the boundary of the DL 
region is not well-defined and more class I genes, Primi £t al., (1979), 
Ivanyi and Demant (1979), or even additional class II loci, O'Neill and 
Parish (1981), may be present. VJhether the cellular response is under the 
same control as that of the humoral response is unclear. Kipps et al., 
(1980) have shown that there can be separate genes controlling the humoral 
and cellular response to the same antigen. The evidence presented here 
seems to corroborate that of Krco in establishing the role of the "D" 
region in the response to the intact molecule. Additionally, although the 
role of the lA region in the humoral response is not defined by the mice 
used, the information gained does not rule out its possible involvement as 
well. 
When a comparison is made between the pattern of response seen with 
HbAj, with that found with HbS, no difference is found. There is little, 
if any, difference in the magnitude of the responses to the two molecules 
(Table 12). This would indicate that the NHg-terminal octapeptide plays 
little role in the control of the humoral response to the intact molecule 
or, if it is involved, that the valine substitution does not effect its 
recognition by the immune system. 
The later conclusion Is drawn into question since numerous groups have 
been successful in raising polyclonal antisera that recognize the HbS 
molecule and not the HbA^  molecule, thus signifying the antigenic nature of 
the valine substitution (Papayannopoulou et al., (1970), Curd et al., 
(1976), Karol et.fA" » (1977), and Carver et al., (1980)). That murine 
antibody is produced against these peptides is shown in Table 15. Of the 
five strains tested, the B10.D2 mice were high responders and the BIO.BR 
156 
and BIO.S mice, low responders. One of the strains, BIO, showed a 
significant decrease in the amount of antibody directed against the g® 
A 
peptide, when compared against the g 1 peptide antibody levels (Table 13). 
This is an Interesting observation because it suggests that the regulation 
of the Immune system may be specific enough to be affected by a single 
amino acid change. It also indicates that separate antigenic epitopes can 
be under separate Ir gene control, an observation reported previously 
(Krco et al., 1982, Okuda et al., 1979, Adorlnl et al., 1979). 
Murine Monoclonal Antibodies to Human Hbs 
During the production and characterization of the many monoclonal 
antibodies used in this study, three interesting, and at times frustrating, 
observations were made concerning them. The first was the high percentage, 
82%, of IgM antibodies, even after months of immunizations. Secondly, 
competition assays, using unbound Hb, were Ineffective in blocking the 
binding of antl-Hb antibodies to Hb coated on the ELISA plates. Finally, 
some of the antibodies were found to bind mouse Hb as well as human Hb. 
The preponderance of IgM antibodies was found to be consistent 
throughout these experiments. Even after 3 months of ip boosts of antigen, 
the only antl-Hb antibody subclass isolated from many of the fusions was 
IgM. The question arises; is this a coincidence, an artifact of the 
screening procedure. Immunization route and schedule, or is there something 
inherent within the Hb molecule that would preferentially Induce an IgM 
response? 
The possibility that this result could be a coincidence is unlikely 
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due to the large number of monoclonal antibodies developed. Another 
explanation would be that the screening procedure used was preferential to 
IgM. Although this would be an easy answer, it is not necessarily the 
correct one. For example, the ExMGG used as the second antibody was 
directed against both heavy and light chains of murine IgG. It would 
recognize IgM, but only by the light chains present. When tested against 
IgM and the IgG subclasses in Ouchterlony analysis, the IgG bands were more 
distinct than the IgM bands, indicating a higher affinity for the IgGs. 
Another problem with the suggestion that the assay was at fault is 
that the sensitivity of the final assay approached lOng. Since the average 
hybridoma secretes at least 1-5 yg/ml of antibody, even weakly positive IgG 
wells should have shown up as positive, yet only one was found. A possible 
problem with the assay, however, may have laid in the ExMGG antiserum. 
When it was tested against the IgG3 subclass, a precipitin line of markedly 
less intensity was found. If the Hb molecule, or at least the 
predominantly recognized determinant(s), were T-independent antigen(s), the 
majority of antibody produced against it would be IgM or IgG3, Slack et al., 
(1980). If the screening antiserum was low in anti-IgG3 antibody, the IgGS 
producing clones would probably have been missed, even with the reactivity 
of the anti-light chain antibodies present. 
A further reason why the vast majority of antibodies were IgiM may be 
the glycosylation of the Hb molecule (Wajcman and Kitzis, 1980) since 
Sharon et al., (1983), have demonstrated a high incidence of IgM or IgA 
antibodies against carbohydrate moieties. Others (Ozato and Sachs, 1981) 
have suggested that the isotype expressed by an antibody may be controlled 
by the MHC, while Bohn and Konig (1982) have suggested the route and 
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schedule of immunization is Involved in isotype expression. 
Perhaps the most serious problem that was encountered, in this work, 
was the inability to absorb out the antl-Hb monoclonal antibodies in a 
competition ELISA. This result indicates one of three possibilities: 1) 
that the antibody was not against the Hb molecule, but bound nonspecifi-
cally to the solid support, or 2) that the affinity of the antibody for the 
Hb molecule was enhanced by Its binding to the plate, or finally, 3) that 
the IgM molecule could not be saturated with antigen in solution, due to 
sterlc hindrances, etc., but could bind additional antigen when the Hb was 
bound to the plate, thereby altering its conformation. 
The first possibility was discounted when controls were done which 
showed that the antibodies did not bind to BSA or to gelatin, proteins used 
as blocking agents. This indicates there was no nonspecific binding to the 
plate itself, nor to the proteins. Only when Hb was used as the antigen 
was a positive reaction seen. As the concentration of this antigen de­
creased, Figure 30, the absorbance also decreased, suggesting binding to 
the molecule Itself. 
If this binding was nonspecific to the Hb molecule, one would assume 
it should be easy to absorb out the antibody using Hb in solution, but such 
was not the case. Thus, it is unlikely that reactivity of the antibodies, 
after absorption, was due to nonspecific binding. 
The possibility that binding the antigen to a solid support may change 
its affinity for antibody may be another explanation for these results. 
Moyle et al., (1983) has demonstrated that the binding of antibodies to a 
solid support may enhance their affinity for antigen. The mechanism of 
this is unclear, but the possibility remains that if an antibody's affinity 
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for antigen can be enhanced, perhaps the antigen's affinity for antibody 
can also be increased. Another possibility would be that when antigen is 
injected into an animal, in complete Freund's adjuvant, neoantigenic sites 
are exposed that aren't found on the original antigen (Lando ^  al., 1982 
and Atassi aj^., 1983). If the monoclonal antibodies were against such 
a site, perhaps the binding of the antigen to the plate would expose the 
neodetermlnant, whereas it would not appear when Hb is in solution. 
Additionally, the decavalent nature of the IgM molecule may allow the 
binding of one Hb molecule per monomer, with the second active site being 
inhibited sterically. When Hb is bound to the plate, a slight change in 
the conformation may negate this hindrance and allow binding. Such 
allosteric Interference is suggested by the work of Giles al., (1983). 
They found that some IgM antl-DNP monoclonal antibodies would have 5 high 
affinity and 5 low affinity binding sites. They suggested that a llgand-
Induced conformational change may affect the affinity of the other monomer 
binding site for the ligand. In the case of Hb, perhaps the binding of the 
Hb molecule to the solid support allows a decrease in this type of 
Interference, thereby allowing binding of the attached Hb and not the lib in 
solution. 
Whatever the explanation, the observations are puzzling. It does 
seem, however, that the inability to inhibit the binding of the antibodies 
to the Hb molecule is more likely a result of the IgM molecule itself and 
not a nonspecific binding effect. 
A final observation is that some of the antibodies bind to murine Hb 
(Tables 17 and 18, pages 145 and 155). This suggests either the presence 
of autoantibodies specific for murine Hb that also react with human Hbs, or 
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that there are determinants present on the human Hb molecule that are 
similar to those found on the Hb of the mouse. The first Instance might 
arise since Hb is not normally found in serum, but is compartmentalized in 
erythrocytes. During disease or trauma, some Hb may be released into the 
serum, but normal catabollsm of the Hb occurs within the extravascular or 
reticuloendothelial system (Lehmann and Huntsman, 1974). Its presence, in 
the serum, as free Hb, or as a haptoglobin-Hb complex, might be sufficient 
to elicit a humoral response. 
The second possibility, that anti-Hb antibodies recognize human 
Hb-llke determinants on mouse Hb, is supported by Twining et al., (1980, 
1981). Using anti-sperm whale myoglobin (SMb) antibodies obtained from 
various species, they demonstrated that the same antigenic sites were 
recognized by all of the antisera, regardless of the antisera's species of 
origin. They suggested that this was due to the immunodomlnance of 
structural, conformational determinants over sequential determinants. They 
also showed that if SMb-primed T cells were challenged with Mb from other 
species, significant amounts of T cell proliferation were seen, even when 
Mbs, vastly different in their primary structures from SMb, were used. 
Additional analysis showed that in the majority of these Mbs, approximately 
the same five antigenic sites were recognized by the T cells (Atassi et 
al., 1981), again suggesting the greater importance of the structural 
location of the antigenic determinant. 
Antigenic Map of the Hemoglobin Molecule 
The second goal of this research can now be addressed, that of defin­
ing a partial antigenic map of the Hb molecule. To establish this profile, 
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polyclonal antlsera and monoclonal antibodies were tested against a series 
of Hb variants, many differing in only a single amino acid, as well as 
against the Individual subunits of the molecule. 
It is not within the scope of the investigation to definitively 
identify all the antigenic determinants on the molecule. It is also 
acknowledged that some of the amino acid substitutions may not be directly 
involved in a determinant but may indirectly affect the conformation of the 
molecule and thereby prevent antibody binding. It may also occur that the 
substituted residue would be part of a determinant, but would not substan­
tially change Its character. Therefore, the positions of the antigenic 
determinants are only suggestions and further investigations need to be 
done using additional monoclonal antibodies and Hb variants before the 
final locations can be pinpointed. 
The data presented in Table 16 (page 140) summarize the responses of 4 
polyclonal antlsera to the variants. The differences observed are not due 
to any increase or decrease in the amount of Hb bound to the well, but 
rather to the effect the amino acid substitution had on the antigenicity of 
the molecule. The five Hbs tested in Figure 30 (page 139) all have 
different electrophoretlc patterns and different pis. Yet all were found 
to show a concentration of 0.1 pg/ml to 1.0 yg/ml of antigen sufficient to 
saturate the wells. Had the effect of charge been an Important 
consideration, the amount of Hb necessary to reach saturation would vary. 
A general observation concerning the overall antigenicity of the 
individual subunits is that the polyclonal antlsera bound more efficiently 
to the a chain than to the B chain. This would signify that the ct chain 
determinants were more antigenic, overall, than the 3 chain determinants. 
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or that there were more determinants present on the a chain than the g 
chain. Of the 27 Hbs tested, only two, Hbl and Hb D-LA, showed a signifi­
cant reduction In their ability to bind the polyclonal antisera. Two of 
the strains, C57BL/10Sn and BALB.B, showed this reduction with Hbl and one, 
BIO.A, with Hb D-LA. The B10.D2 antiserum was not affected. 
This difference in response suggests a possibility of separate Ir gene 
control for each determinant. Others (Infante et al., 1981 and Berzofsky, 
1982) have also shown such individual control against separate Mb epitopes. 
It is interesting to note that the a chain variation in Hbl lysglu), 
is found in an area suggested to be antigenic by others (Kazim and Atassi, 
1980). One can speculate that the lys glu switch effectively disrupts the 
conformation of this site. It is also possible that since the B10.D2 and 
BIO.A antisera do not show a decrease in binding when tested against this 
Hb, that either the mice do not respond to this determinant, or that their 
response is significantly lower than that directed toward other 
121 determinants. The decreased binding of the BIO.A sera toward Hb D-LA (3 
glu+gln) suggests the presence of an antigenic determinant in this region. 
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However, if the response to Hb Beograd is examined (g glu-vval) no 
difference is seen. This residue is involved in a salt bridge with the 0^  ^
lysine of the same chain, thereby stabilizing the molecule (Lehmann and 
Kynoch, 1976). Perhaps the loss of polarity and the charged side chain in 
Hb Beograd will not affect the stability of the molecule, whereas the loss 
of charge alone and the presence of a large, polar side chain, will 
sterically disrupt this portion of the chain. It also may be that this is 
a case of an amino acid substitution affecting a determinant of which it is 
not a part. 
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It is apparent from the polyclonal antlsera's reactivities, that the 
great majority of the Hb variants have little or no effect on the overall 
antigenicity of the molecule. The amino acid substitutions may affect the 
antibody produced to a single epitope, but the total antibody population 
remains virtually unchanged. When examining the monoclonal antibodies 
(Mab) reactivities, however, significant and varied responses are seen. 
The first conclusion to be drawn from the Mab data. Tables 17 and 18 
(pages 145 and 155), is that the a chain appears to be a more immunogenic 
portion of the molecule. Eight of 10 antibodies tested were directed 
against the o, chain. This may be due to preferential orientation of the a 
chain when bound to the solid support, or, as was demonstrated earlier, the 
immune response of the B10.D2 mice used is higher against the a chain. The 
higher response to the o chain is interesting since the primary structure 
of the mouse's a chain differs with the human a chain in only 16 of 141 
amino acids, whereas the 3 chain differs in 26 of 146 residues. If the 
antigenicity of a protein depends on sequence differences between the 
injected protein and its counterpart in the host, then one would expect a 
higher antibody titer to the P chain than to the a chain, as opposed to 
what is found here. 
The question of whether antigenicity is dependent more on differing 
primary structures than on the tertiary structures of the molecules in 
question has been raised by a number of groups. Two of the groups, 
Margoliash at Northwestern University and Atassi at the Mayo Clinic, have 
presented opposing viewpoints. Urbanski and Margoliash (1977) and 
Jemmerson and Margoliash (1979) have raised antibody to guanaco cytochrome 
c (cyt c) and horse cyt c in rabbit. These proteins differ In 1 or 2 amino 
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acids respectively, from rabbit cyt c. It had previously been assumed that 
any antibody raised against these immunogens would be directed against 
portions of the molecule containing the different residues, as they 
suggested. Atassl (1981), however, used peptides homologous to regions of 
beef cyt c that contained amino acids (3) that differed from rabbit cyt c. 
Only one peptide bound to antibody raised against the intact cyt c 
molecule. When the antiserum was checked for cross reactivity with rabbit 
cyt c, a substantial amount of binding could be found. This suggested that 
the antigenicity of the molecule was not due to the differences in amino 
acid sequence, but to structurally dependent determinants, which were 
present on rabbit cyt c as well. This would tend to corroborate the 
binding to mouse Hb found with some mouse antl-Hb Mab. 
The lower antigenicity of the g chain in BI0.D2 mice, might also 
explain, in part, the inability to isolate a hybridoma that produced 
antibody specific for either HbA^ or HbS. The problems associated with 
clone lA, which recognized both the g^ l and 3^ peptides, have already been 
discussed in the results section, and are sufficient to suggest that the 
binding of the antibody to the peptides may have been an artifact. A 
future way of isolating such an antibody has been suggested by the recent 
work of Young et al., (1983a,b) and Schmltz et al., (1983). Using purified 
peptides of selected regions of Mb as Immunogens, and a sensitive solid 
phase radioimmunoassay, they have demonstrated the selective production of 
antibodies capable of recognizing both the native Mb antibody and the 
peptide. This reactivity was specific for the peptide and no cross reac­
tivity with other peptides was observed. The use of peptides representing 
nonlramunogenlc areas of the molecule also succeeded in raising a response 
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that recognized both the peptide and the Intact molecule. They extended 
this work to develop mabs of predefined specificity. The ability to 
demonstrate such a response to a small molecular weight antigen, without 
first coupling to a larger carrier molecule, suggests that the minimum size 
of an antigen necessary to elicit an immune response is much less than pre­
viously thought, Singh et al., (1980). It also suggests that any portion of 
a particular molecule may be antigenic if presented in the proper manner. 
The variant Hbs can be classified into 3 groups, based on their 
ability to inhibit the binding of the mabs. The first group, those Hbs 
that do not significantly affect the binding of the antibody, contains Hb 
G-Philadelphla and HbAj^ . The non inhibitory nature of this group with 10 
antibodies suggests that the asparagine or the 3^ glutamic acid, lies 
outside of an antigenic region recognized by the antibodies, or that they 
do not affect the conformational character enough to inhibit the binding of 
the Mab. Kazim and Atassi, 1980, have shown the presence of an antigenic 
site In the region thus suggesting the nonantigenlc nature of the 
asparagine. Although the ability to produce antibody to the 3 chain's 
N-terminal end has been demonstrated elsewhere. Curd et al., (1976) etc., 
and possibly in this work as well, it seems apparent that the antigenic 
role this region plays Is minimal. 
The next group of Hbs are those that affect the binding of only 1 or 2 
antibodies. Their variant residues may be considered as important anti­
genic residues which lie close to, or within an antigenic site. The 
substitute amino acids of Hbs Hasharon, Montgomery and Russ all lie within 
the 2nd antigenic site postulated by Kazim and Atassi, 1980. This area is 
a nonhellcal region of the a chain which lies on an external "corner" of 
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the molecule (Figure 5) and is therefore highly accessible. Of the three 
antibodies affected by these substitutions, 6, 8, 10, all are directed 
against the a chain, though 2 are affected by 3 chain substitutions. Only 
#6 is unaffected by changes in the 3 chain, and therefore could be consid­
ered to be directed against this area on the molecule. It is interesting 
that the substitution of the 3 chain with the 6 chain, inhibits binding of 
6 and 10, while no affect is seen with 8. Perhaps the 6 chains interaction 
with the a chain affects the nature of these two binding sites. 
95 Another Hb in the second class is G Georgia. The a pro + leu 
substitution would seem to be a drastic one, since the proline is involved 
in the contact region of the 3^ subunits. It is also found, therefore, 
in the central cavity of the molecule and as such is unlikely to be in­
volved in any antigenic determinants, at least those appearing prior to 
processing by the macrophage. The one antibody affected, #4, may recognize 
a determinant located elsewhere in the molecule, probably on the 3 chain. 
Hbs J-Baltimore (3 gly •> asp) and D Iran (3 glu glu) affected 
the binding of two antibodies each, 5 and 10 and 4 and 10 respectively. 
Both of these residues have been suggested to be in an antigenic determin­
ant on the a chain (Kazim and Atassi, 1980). Since the determinants on the 
a chain closely resembled those on the Mb molecule, and since the g chain 
also closely resembles the Mb molecule in tertiary structure, the proba­
bility of similar antigenic determinants, based on structural location, is 
high. Therefore, there is a good chance these residues would lie close to, 
or within a determinant. 
HbC and Hb Beograd are the last two Hbs in the second class. HbC, 3^ 
glu lys, inhibits one Mab, 7, while enhancing the binding of 8 and 10. 
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This enhancement of binding, found in a couple of other Hbs, may be due to 
the exposing of an antigenic site partially masked in HbS but uncovered 
when processed by the macrophage or other antigen presenting cell. When 
bound to a solid support, the determinant may not be oriented in a way that 
would facilitate binding of antibody. The lysine substitution, on the 
other hand, may open up the molecule or orient it in such a way that the 
site would be more preferentially exposed. This is, of necessity, specula­
tion, but does seem to fit the data. The possible role of Hb Beograd has 
already been discussed. 
The third class of Hbs, those affecting the binding of more than 1 or 
2 antibodies, contains Hbs I, Arya, Zurich, N-Baltimore and D-LA. Half of 
the Nabs are affected by Hbs I and N-Baltimore, 70% by Hbs Arya and D-LA. 
Hb Zurich decreases the binding of 4 of 10 mabs. Since such a large 
proportion of the mabs are affected, it is reasonable to assume that these 
substitutions affect the entire conformation of the molecule and therefore 
63 its determinants. Hb Zurich, g his arg, for example, affects a con­
served residue that interacts with the heme molecule (Lehmann and Kynoch, 
1976). The loss of the histldlne may cause a significant shift in the heme 
group and therefore may affect the surrounding structure. Hb Arya, asp 
-v asn, is located in the same position as Hb Hasharon, yet Hasharon affects 
only one Mab while Arya affects 7, suggesting a major shift in the struc­
ture of the molecule, not accomplished by the asp his of Hasharon. 
A final observation concerns the Hbs A^, F and met HbS. The inter­
action of the 6 chains with the a chain can affect the binding of both a 
chain and 3 chain specific antibodies. The same can be said about the y 
chain of HbF. One would expect, however, that the 37 amino acid differ­
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ences of the y chain would tend to make more of a difference than do the 
nine substitutions of HbA^ . Instead, both Hbs affect 50% of the mabs, 
23 three of which are the same. This suggests that the a residue, the only 
one which is different in both the 6 and y chains, may play an important 
role in the regions recognized by mabs 4, 5 and 7. It also appears as 
though the valence of the Fe is only of minor importance in the 
antigenicity of the protein. 
When an attempt is made to define the binding specificities of the 
various mabs, it readily becomes apparent that precise definition is 
impossible and, for the majority of antibodies, general definition Is 
impractical. There is, however, 1 antibody that shows some unique re­
activity patterns. Mab 7, a g chain-specific antibody, shows different 
reactivities with only 3 g chain variants and no a chain variants. One of 
the variants, D-LA, seems to exert a generalized effect on most of the 
mabs, whereas HbC and HbE exert minimal distortion. It is suggested, 
therefore, that Mab #7 recognizes a determinant located in the N-terminal 
end of the 0 chain, within the first 26 amino acids. 
Conclusion 
Seven basic conclusions can be drawn from this research. 1) The 
humoral response to human Hb is under the control of genes residing within 
and outside of the major histocompatibility complex H-2. 2) Within the H-2 
region, at least one gene maps to the D end of the complex, suggesting a 
role for class I antigens in the control of the antibody response. 3) The 
immune response to the subunits of Hb are controlled by different H-2 
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gene(s) since high responders to the Intact molecule. I.e., B10.D2 mice, 
are lower responders to the 0 chain. 4) When comparing the T cell 
proliferative response to Hb subunits to the humoral response, it appears 
as though the humoral and cellular responses are under different Ir gene 
control. 5) Some monoclonal antibodies directed against human Hb recognize 
similar determinants on native mouse Hb, suggesting that the amino acid 
sequence is not critical in determining what areas on the molecule are 
antigenic, but rather the overall conformation of the molecule is the 
determining factor in antigenicity. (6) Hb elicits a high IgM response 
which may be caused by its glycosylatlon or the screening assay's 
specificity and/or sensitivity. 7) The use of Hb variants as probes to 
determine the location of antigenic determinants has limited usefulness 
since single amino acid substitutions can radically interfere with 
determinants relatively far away on the molecule from the substitution. 
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